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Abstract 
 
Zubakova Radka, pharmacist                                 oral examination on 15th May 2007  
 
ANALYSIS OF THE MECHANISMS INFLUENCING THE EXPRESSION OF 
BLOOD PRESSURE REGULATING SYSTEMS 
 
Referees: Prof. Dr. Ulrich Hilgenfeldt, Prof. Dr. Gert Fricker 
 
Several hormonal and autocrine systems are involved in the physiology and 
pathophysiology of blood pressure regulation and salt-water homeostasis including 
the renin-angiotensin-aldosterone system, the kallikrein-kinin system, nitric oxide and 
the adenosine system. 
Within the scope of this project, the influence of high salt diet and aldosterone on the 
regulation of NO, NO synthase, adenosine-, and bradykinin-receptors should be 
examined in kininogen-deficient BNK rats and in control BN rats. For 10 days BNK 
and BN rats were given a standard or high salt diet in presence or absence of the 
aldosterone antagonist, spironolactone.  Gene expression analysis was performed in 
tissue of kidney, atria, and ventricles using real-time RT-PCR. The activity of NO 
synthase was elicited by measuring NO metabolites in urine and plasma. In addition 
in a HEC cell line we measured the effects of different kinins on the bradykinin B1- 
and B2-receptor of rat, mouse and human via analysing fluorometrically the 
intracellular calcium influx.  
We found lower NOx production in plasma and urine of BNK rats in almost all 
experimental groups. Moreover, we could determine that in the kidney of BNK but not 
of BN rats high salt diet down-regulated the expression of nNOS and iNOS. The 
decreased NO level might be one of the factors responsible for the salt-sensitive 
hypertension in kininogen-deficient BNK rats.  
Furthermore, expression analysis of the kidney showed, that aldosterone plays an 
important role in the regulation of A1AR, A3AR and of nNOS. An increased salt intake 
seems to have no significant effect on renal adenosine receptors, NOS and B2R. 
Nevertheless, we found that high salt intake significantly up-regulated B1R in BN, but 
not in BNK rats. The enhanced B1R expression after high salt diet in the kidney of BN 
rats might have a protective effect. Down-regulation of A3AR and nNOS in ventricles 
of BNK rats after increased salt intake in BNK rats is probably one of the reasons for 
the increased cardiac sensitivity towards ischemia. 
We conclude that the lower NO levels and altered gene expression in kininogen- 
deficient BNK rats might contribute to the development of hypertension and salt-
sensitivity. Furthermore, we could demonstrate for the first time that in the kidney 
aldosterone plays an important role in the regulation of A1AR, A3AR and nNOS.  
In addition, we showed that the efficacy and potency of BK, KAL and KLP on the B2R 
is similar in rat, mouse and human. Moreover, we demonstrated that des-Arg9-BK, 
des-Arg10-KAL and des-Arg10-KLP display similar effects on the B1R of rat, mouse 
and human.  
Zusammenfassung  
 
Zubakova Radka, Apothekerin                             mündliche Prüfung am 15. Mai 2007 
 
ANALYSE DEN MECHANISMEN DIE DIE EXPRESSION VON 
BLUTDRUCKREGULIERENDEN SYSTEMEN BEEINFLUSSEN 
 
Gutacher: Prof. Dr. Ulrich Hilgenfeldt, Prof. Dr. Gert Fricker 
 
An der Regulation von Blutdruck und Salz-Wasserhaushalt sind verschiedene 
hormonelle  und autokrine Systeme beteiligt, einschließlich das Renin-Angiotensin-
Aldosteron System, das Kallikrein-Kinin System, Stickstoffmonooxid (NO) und das 
Adenosin System. 
Im Rahmen diese Dissertation sollte in Kininogen-defizienten BNK Ratten und in BN 
Kontrollratten der Einfluß einer Hochsalz-Diät und von Aldosteron auf die Regulation 
von NO, NO-Synthasen, Adenosin- und Bradykinin-Rezeptoren untersucht werden. 
Im Zeitraum von 10 Tagen wurden BN- und BNK-Ratten mit einer Standard- oder 
Hochsalz-Diät gefüttert und gleichzeitig mit oder ohne Spironolacton behandelt. Der 
Nitrat- und Nitrit-Spiegel (NOx) wurde in Plasma und in Urin mittels eines NO-
Fluoreszens Kits gemessen. Im Gewebe von Niere, Atrium und Ventrikel wurde die  
Expression der NOS, der Adenosin- und Bradykinin-Rezeptoren mittels real-time 
PCR gemessen. Außerdem analysierten wir in einem HEC-Zellmodell die Wirkungen 
verschiedener Kinine auf den Bradykinin B1- und B2-Rezeptor von Ratte, Maus und 
Menschen mittels einer quantitativen fluorimetrischen Bestimmung der intrazelluläre 
Kalzium Konzentration. 
In Plasma und Urin weisen BNK Ratten im Vergleich mit BN Ratten eine niedrigere 
NOx auf. Außerdem konnten wir zeigen, dass in der Niere von BNK Ratten 
Hochsalz-Diät zu einer verminderten Expression von nNOS und iNOS führt. 
Verminderte NOx Spiegel und verminderte NOS Expression könnten ein Grund für 
die Salz-abhängige Hypertonie in Kininogen-defizienten BNK Ratten sein. 
Ferner zeigte sich, dass Aldosteron in der Niere eine wichtige Rolle in der 
Regulationen der Expression von A1AR, A3AR und der nNOS spielt. Hochsalz-Diät 
scheint keine signifikante Wirkung auf die Expression der Adenosin-Rezeptoren, der 
NOS und der B2R in der Niere zu haben. Wir konnten zeigen, dass Hochsalz-Diät zu 
einer erhöhten B1R Expression in der Niere von BN Ratten, aber nicht von BNK 
Ratten führt. Die B1R Überexpression nach einer Hochsalz-Diät in der Niere von BN 
Ratten könnte eine Schutzwirkung haben durch eine erhöhte Kinin-abhängige NaCl-
Auscheidung. Außerdem finden wir nach Hochsalz-Diät im Ventrikel von BNK Ratten 
eine verminderte Expression der A3AR und nNOS. Das könnte im Zusammenhang 
stehen mit einer erhöhten Ischämieempfindlichkeit und eine Ursachen der Salz-
abhängigen Hypertonie in BNK Ratten sein.  
Zusammenfassend scheint der niedrigere NOx Spiegel  und die  verminderte nNOS 
und iNOS Expression in Kininogen-defizienten BNK Ratten eine Ursachen für den 
Salz-abhängigen Blutdruck sein. Außerdem scheint Aldosteron in der Niere beider 
Rattenstämme die Expression von A1AR, A3AR und nNOS beteiligt zu sein. 
Außerdem konnten wir zeigen, dass die Wirksamkeit und Potenz  von BK, KAL und 
KLP auf dem B2R der Ratte, Maus und Menschen ähnlich sind. Weiter haben wir 
gezeigt, dass des-Arg9-BK, des-Arg10-KAL und des-Arg10-KLP ähnliche Wirkungen 
und Potenz auf den B1R der Ratte, Maus und Menschen aufweisen. 
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1. INTRODUCTION 
 
Hypertension is a major risk factor for the development of cardiovascular diseases, 
such as coronary heart disease, congestive heart failure, and peripheral vascular and 
renal diseases. Despite extensive animal and clinical investigations, the mechanisms 
of the normal regulation of arterial pressure and development of essential or primary 
hypertension are far from being elucidated. 
One basic concept was favoured by Guyton and other authors: the long-term 
regulation of arterial pressure is intimately linked to the ability of the kidneys to 
excrete sufficient sodium chloride to maintain normal sodium balance, extracellular 
fluid volume, and blood volume. Many different extrinsic influences and intrarenal 
derangements can lead to reduced sodium excretory capability. Many factors also 
exist that alter cardiac output, total peripheral resistance, and cardiovascular 
capacitance. Accordingly, hypertension is a multifactorial dysfunctional process that 
can be caused by a myriad of different conditions (Navar et al., 1999).  
 
 
 
Fig.1.1: Volume determinants of arterial pressure. Two major determinants of arterial pressure, 
cardiac output and total peripheral resistance, are regulated by combination of short- and long-term 
mechanisms (Navar et al., 1999). 
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The basis for a rational approach to the treatment of hypertension is limited with an 
understanding of the normal mechanisms regulating sodium balance and how 
derangements lead to altered sodium homeostasis and hypertension. 
In this work we have focused on the role of kallikrein-kinin system (KKS), nitric oxide 
(NO) and nitric oxide synthases (NOS), adenosine system and rennin-angiotensin-
aldosterone system (RAAS) in the blood pressure regulation. 
  
1.1. KIDNEY AND SALT  
 
The importance of sodium in the pathophysiology of hypertension has been revealed 
by several sources, including large epidemiological analyses, interventional trials, 
and a large body of experimental and clinical evidence. According to Guyton´s 
hypothesis, a shift of the pressure-natriuresis curve has been described in all forms 
of hypertension, suggesting, that the ability of the kidney to excrete sodium must be 
altered in hypertension. Yet, the intrarenal mechanism responsible for the abnormal 
salt excretion remains unknown.  
 
 
 
Fig.1.2: Sodium (Na+) reabsorption along the mammalian nephron. About 60% of Na+ is reabsorbed 
along the proximal tubule (PROX), about 25% along the loop of Henle (LOH), about 5% to 7% along 
the distal convolute tubule (DCT) and 3% to 5% along the collecting duct (CD) system. All Na+ 
transporting cells along the nephron express the sodium-potassium adenosine triphosphate (Na-K 
ATPase) pump at their basolateral (blood) cell surface (Navar et al., 1999).  
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Sodium is the predominant cation in extracellular fluid (ECF); the volume of ECF is 
directly proportional to the content of sodium in the body. In principle, sodium 
balance can be regulated by altering sodium intake or excretion by the kidney. 
However, intake is dependent on dietary preferences and usually is excessive 
because of the abundant salt content of most foods. Therefore, regulation of sodium 
balance is achieved primarily by altering urinary sodium excretion (Navar et al., 
1999).  
Many different neurohumoral mechanisms, paracrine factors, and drugs can 
influence sodium excretion and the pressure natriuresis relationship. These 
modulators may influence sodium excretion by altering changes in filtered load or 
changes in tubular reabsorption. Filtered load depends primarily in hemodynamic 
mechanisms that regulate the forces operating at the glomerulus. The glomerular 
filtration rate is determined by the filtration coefficient and the filtration pressure. The 
filtration coefficient is regulated by neural, humoral and paracrine components.  
 
FACTORS AFFECTING VASCULAR TONE 
  
Constrictors:  Dilators: 
Angiotensin II         Nitric oxide 
Catecholamines   Prostacyclin    
Endothelin-1                    Bradykinin 
Cytokinins   EDHF 
EDCF    Adenosine A2AR 
ATP Dopamine 
Adenosine A1AR   
 
Tab.1.1: Factors affecting vascular tone. EDCF, endothelium derived hyperpolarizing factors, ATP, 
adenosine triphospate, EDHF, endothelium derived constricting factors (www.hypertensiononline.org).  
 
Derangements in tubular transport mechanisms can cause hypertension even in the 
absence of overt reductions in renal hemodynamics. Under normal conditions, less 
than 1% of the filtered sodium load is excreted, and small percentile changes in the 
fractional sodium reabsorption can translate into large changes in daily sodium 
excretion. Changes in tubular reabsorption can result from alterations of various 
processes governing both active and passive transport of sodium along the nephron 
segments.  
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Fig.1.3: Mechanism of sodium chloride reabsorption in collecting duct. Sodium transport in the 
collecting duct is mainly via amiloride-sensitive sodium channels in the apical membrane. The 
basolateral sodium-potasium ATPase creates the driving force for overall sodium transport. Regulation 
of sodium channels may involve either insertion (from subapical compartments) or activation of 
preexisting sodium channels (Navar et al, 1999). 
 
There is also evidence that exist genetically linked forms of hypertension. Several of 
these generically linked forms of hypertension involve a single gene mutation, which 
allowed their analysis by molecular genetic approaches. Some genetic defects lead 
to inhibition and some to over-expression or over-activity of specific proteins involved 
in the tubular reabsorption of sodium (Navar, 2005).   
 
1.2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM 
 
The renin-angiotensin-aldosterone system (RAAS) serves as one of the most 
powerful regulators of arterial pressure and sodium balance. Renin is synthesized 
and released by the juxtaglomerular cells in the afferent arteriole of the kidney in 
response to a decrease in intravascular volume detected by baroreceptors and by a 
reduced sodium concentration at the macula densa. Renin catalyses the hydrolysis 
of angiotensinogen to angiotensin I which is then converted to angiotensin II by 
angiotensin-converting enzyme (ACE), present in the lungs and vascular tissue. 
Angiotensin II acts on vascular smooth muscle to cause vasoconstriction, and on the 
adrenal zona glomerulosa to stimulate aldosterone production. 
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Classically, aldosterone acts on epithelial cells, particularly in the renal collecting 
duct, but also in the parotid gland and in the colon, where it regulates electrolyte and 
fluid balance and subsequent blood-pressure homeostasis. Aldosterone binds to 
specific intracellular mineralocorticoid receptors, which belong to the 
steroid/thyroid/retinoid family of nuclear receptors. The hormone-receptor complex is 
translocated  to the cell nucleus, where it modulates gene expression and translation 
of specific ´aldosterone-induced´proteins. The modulated expression of ´aldosterone-
induced´proteins leads to increased Na+/K+ adenosine triphosphate activity at the 
basolateral membranes and increased sodium channels on the luminal membrane 
(Connell, 2005). 
 
 
 
Fig.1.4: Effects of aldosterone on distal nephron sodium reabsorption (Navar et al, 1999). 
 
In the CNS aldosterone appears to regulate blood pressure, salt appetite and 
sympathetic tone. Aldosterone in the cardiovascular system promotes cardiac 
hypertrophy, fibrosis and abnormal vascular endothelial function (Delcayre, 2000, 
Brilla, 1993, Weber, 2000). In cultured vascular smooth muscle cells stimulated by 
the cytokine interleukin-1-beta, aldosterone inhibits nitric oxide formation and 
inducible nitric oxide synthase mRNA (Ikeda et al., 1995).  
The clinical significance of these effects of aldosterone on cardiovascular function 
was emphasized by the Randomized Aldactone Evaluation Study, which 
demonstrated that inhibition of aldosterone action (using spironolactone) was 
associated with a 30% reduction in mortality rates in patients with heart failure after 
myocardial infarction (Pitt et al., 1999).  
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1.3. KALLIKREIN-KININ SYSTEM 
 
1.3.1. Components of the KKS and their effect 
 
The kallikrein-kinin system consists of the precursor kininogens, the proteolytic 
kallikrein enzymes, the kinin peptides and two kinin receptors. With respect to 
functional aspects, the KKS can be divided into a plasma KKS and a tissue KKS. It is 
well accepted that kallidin is released from low-molecular-weight (LMW) kininogen by 
the action of tissue kallikrein (KAL) and bradykinin (BK) from high-molecular-weight 
(HMW) kininogen by the action of plasma kallikrein (Marceau and Regoli, 2004). 
The kallikrein-kininogen-kinin system (KKS) controls blood pressure regulation, 
sodium and water excretion, and promotes inflammation and pain in pathological 
conditions. Kinins are very potent vasodilators. Most circulatory effects of BK-related 
peptides are determined by the stimulation of endothelial cells from witch secondary 
mediators are released (endothelium-derived relaxing factor, NO, prostacyclin) to 
affect the vascular smooth muscle (Marceau and Regoli, 2004). 
 
 
 
 
Fig.1.5: Schematic representation of the KKS (Marceau and Regoli, 2004). 
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1.3.2. Kinins and kinin receptors 
 
Most effects of kinin are likely mediated by the activation of two G-protein-coupled 
receptors (GPCRs): B1R and B2R. The physiological ligands acting on B2R in 
humans are bradykinin (BK) and kallidin (KAL). In contrast, BK is believed to be the 
only kinin acting on the B2R in rat and mouse. However, recently a kallidin-like-
peptide (KLP=Arg-BK) was isolated from plasma and urine of rats (Hilgenfeldt et al, 
2005). The naturally occurring metabolites of KAL and BK, des-Arg10-Kallidin (des-
Arg10-KAL) and des-Arg9-Bradykinin (des-Arg9-BK) are binding with high affinity to 
the B1R.   
The pharmacological properties of the B1R in binding the endogenous kinin peptides 
are known to differ across species. Molecular cloning has revealed that these 
pharmacological differences arise from the diversity within the BDKRB gene (Hess et 
al., 2002). The potency order of agonists, as established in separate binding assays 
(Tab.1.2.), confirms that the removal of the C-terminal arginine is essential for high 
affinity on the B1R an detrimental for affinity toward the B2R.  This holds true for KAL 
and des-Arg10-KAL, which have higher affinities for the human and rabbit B1Rs 
compared with BK and des-Arg9-BK, respectively. However, the pharmacology of the 
mouse receptor is unique in that it possesses a 2-3-fold selectivity for des-Arg9-BK 
over the agonist des-Arg10-KAL (Marceau et al., 1998). 
 
                                           Affinity Estimates (Ki)                               
     Human Receptors     Mouse Receptors     Rabbit Receptors 
Peptide B1R B2R B1R B2R B1R B2R 
BK > 10,000 0,54 200 0,48 >5000 4.5 
KAL (Lys-BK) 2.54 0.63 510 0.52 19 2 
des-Arg9-BK 1930 8100 0.7 6400 32 >1000 
des-Arg10-KAL 0.12 >30,000 1.7 25,000 0.23 >1000 
 
Tab.1.2: Affinities of kinins obtained using radioligand binding assay for recombinant kinin receptors 
(Leeb-Lundberg, 2005). 
 
The amino acid sequences of both receptors show an overall homology of only 36%, 
however, with higher areas of homology in the transmembrane regions. Despite their 
relative low homology, the receptors appear to share similar signal transduction 
pathways, such as activation of phospholipase C that leads to the release of inositol 
phosphates and inxrease in intracellular [Ca2+] levels, in response to binding of 
agonists (Faussner et al., 1999). 
 INTRODUCTION 
8 
 
 
Fig.1.6: Signal transduction pathway of B2R and B1R. Following binding of kinins to the receptor the 
associated heterotrimeric G protein complex dissociates. The α subunit stimulates PLC which in turn 
catalyses the breakdown of phosphatidylinositol-4,5-bisphosphonate (PIP2) into 1,2-diacylglycerol 
(DAG) and inositol-1-4-5-trisphosphate (IP3). IP3 reacts with Ca2+ channels in the endoplasmatic 
reticulum (ER) releasing Ca2+  into the cytosol. The increase in intracellular Ca2+  levels activates 
protein PKC, which translocates to the plasma membrane, anchoring to DAG and phosphatidylserine.  
 
Whereas B2R are constitutive entities, B1R behave as key inducible molecules. B1Rs 
are normally absent, but may be highly upregulated following inflammatory stimuli 
(bacterial endotoxin, LPS-12h, ischemia, IL1, TNFαβ). This is an  unusual 
characteristic of G-protein-coupled receptors. In fact, the pattern of induction of B1R 
resembles more closely to tyrosine-kinase-linked receptors. Kinin B1R seem to be 
upregulated under the same conditions described for the inducible proinflammatory 
enzymes (COX-2, iNOS). Some recent reports have indicated, the existence of a 
crosstalk between B1R and B2R. Therefore, evidence has also shown that persistent 
stimulation of B2R may result in B1R receptor upregulation. It is worth noting that 
stimulation of B2R receptors leads to transient increases in Ca2+ concentration and to 
the fast desensitisation of these receptors. Regarding B1Rs, they do not seem to be 
susceptible to desensitisation mechanisms and their stimulation results in sustained 
elevations of Ca2+ concentration (Calixto et al., 2004). 
Both receptor subtypes for kinins can be expressed by the same cell types: vascular 
cells (endothelial, smooth muscle), fibroblasts, epithelial cells, nervous cells, and 
various tumor cells (Leeb-Lundenberg et al., 2005).  
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1.3.3. KKS in the kidney 
 
All components of the KKS are present along the renal tubules, particularly in the 
distal tubules. The tissue kallikrein and kininogen are secreted from the epithelial 
cells of the connecting tubules. The B2R are present mainly on the epithelial cells of 
the medullary collecting duct, but also in the glomerulus, proximal straight tubules, 
cortical thick ascending limb of Henle´s loop, and distal convoluted tubule (Katori and 
Majima, 2003).  
The B1R gene was reported to be present in the kidney (Chai et al., 1996). Under 
physiological conditions almost no B1R could be detected. After induction with 
bacterial lipopolysaccharide (LPS) the expression of B1R-mRNA was strongly 
induced in the efferent arteriole, the medullary thin limb and in the distal tubule 
(Castano et al., 1998). 
Kinins have been implicated in the control of renal blood flow, glomerular filtration, 
and sodium excretion (Scicli et al., 1986). The kinins must be generated directly in 
the kidney, since infusion of the kallikrein did not increase the excretion of kinin in 
man (Yoshinaga  et al., 1964). 
The kallikrein-kinin system is stimulated by sodium depletion, indicating it serves as a 
mechanism to dampen or offset the effects of enhanced ang II levels (Margolius, 
1996). It has been shown that intrarenal infusion of kinins produces an increase in 
renal blood flow as well as diuresis and natriuresis (Gill et al., 1965; Webster and 
Gilmore, 1964). Part of the effect of kinins appears to be mediated by the release of 
prostaglandins. Although glomerulus and distal nephron segments contain both B1R 
and B2R, most of the renal vascular and tubular effects appear to be mediated by 
B2R activation (Navar et al., 1996; Bholla et al., 1992). 
Reduced renal kallikrein excretion has been documented in patients with mild renal 
disease and more markedly reduced in patients with severe renal failure (Price, 
1982; Naicker et al., 1999). Mineralocorticoids as well as the diuretics furosemide, 
bumetanide and bendro-flumethiazide increase, spironolactone decreases kallikrein 
excretion (Distler et al., 1979). 
 
Brown Norway Katholiek Rats 
The role of the renal KKS in the kidney has been clarified, using mutant kininogen-
deficient (Brown  Norway Katholiek, BNK)  rats, which  show low levels of  kininogen,  
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HMW, LMW kininogen and prekallikrein in plasma. Katori and Majima published, that 
BNK rats are almost entirely incapable of excreting kinin in the urine. However, in 
contrast to these findings, our experimental group could detect urinary kininogen as 
well as kinins in urine of BNK rats (data not published). Kininogens and kinins found 
in urine are supposed to be of renal origin. It seems probable that the defect in 
secretion of kininogens is relevant only for the hepatic cells and therefore the 
kininogen-deficiency is present only in plasma.   
The mutant BNK rats show neither apparent physiological disorders nor increases in 
systemic blood pressure compared with that of normal Brown-Norway (BN) rats and 
of rats of other strains, as long as they have a normal NaCl content in their diet. 
Nevertheless, a dietary NaCl content of only 2%, which does not affect blood 
pressure in normal rats, increases it to 170 mm Hg in BNK rats. Sodium 
accumulates particularly in cells, such as erythrocytes, and in body fluid, such as 
cerebrospinal fluid. Importantly, sodium accumulation in the cells increases arteriolar 
sensitivity to ang II and norepinephrine (Majima et al, 1993; Majima et al, 1994). 
 
1.3.4. KKS in the heart 
All the components of the KKS are located in the cardiac muscle, and its deficiency 
may lead to cardiac dysfunction. In recent years, numerous observations obtained 
from clinical and experimental models of diabetes, hypertension, cardiac failure, 
ischemia, myocardial infarction and left ventricular hypertrophy have suggested that 
the reduced activity of the local kallikrein-kinin system may be instrumental for the 
induction of cardiovascular-related diseases. Acting mainly through B2R, kinins may 
counterbalance the pressor effect of ang II, salt, and mineralocorticoids plus salt. 
Studies using ACE inhibitors showed a protective effect of endogenous kinins in the 
development  of cardiac hypertrophy (Linz and Scholkens, 1992). Bradykinin 
administration attenuated infarct size in an isolated perfused heart model of 
ischemia-reperfusion injury (Bell and Yellon, 2003). Furthermore, genetic 
manipulation of KKS components clearly demonstrated a role of this system in 
cardiac function. Tissue kallikrein knockout mice are normotensive, but develop 
cardiovascular abnormalities earlier in adulthood (Meneton et al, 2001). In addition, 
ablation of the kinin B2R gene in mice caused dilated cardiomyopathy followed by 
cardiac failure (Emanueli et al, 1999). 
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The binding of kinins to endothelial B2R leads to the release of NO and PGI2, exerting 
vasodilator, ischemic and anti-proliferative effects, and preserving myocardial stores 
of energy-rich phosphate glycogen (Zhu et al., 1995). Circumstantial evidence also 
suggests that a dysfunctional KKS may contribute to pathogenesis of heart failure. In 
fact, reduced local kinin generation and blunted NO formation have been reported in 
microvessels of failing human hearts (Kichuck et al., 1996). Kinins are continuously 
released during hypoxia and ischemia (Koide et al., 1993).    
1.3.5. KKS, salt and sodium-retaining steroid hormones   
When sodium accumulates in the body, the components of the KKS located in the 
distal tubules of the kidney  start to induce natriuresis and diuresis. Thus it can be 
hypothesized that the system works as a safety valve for sodium accumulation 
(Katori and Majima, 2003). The restriction of salt intake increases the urinary 
excretion of kallikrein (Levy et al., 1977). Prolonged sodium deprivation causes 
aldosterone release through activation of RAAS, and so the increase in kallikrein 
excretion may be mediated by the release of this hormone. Urinary excretion of 
kallikrein is increased in patients with primary aldosteronism (Margolius et al., 1971). 
In addition, treatment of patients with spironolactone, a selective antagonist of 
aldosterone, markedly reduced urinary kallikrein excretion (Seino et al., 1977). 
 
1.4. ADENOSINE SYSTEM 
 
1.4.1. Adenosine 
 
Adenosine is an endogenous nucleoside that modulates a variety of cellular functions 
and is released under conditions of physiological stress. Adenosine is prevalent 
throughout the body. In the periphery, the main effects of adenosine include 
vasodilatation, bronchoconstriction, immunosuppresion, cardiac depression, 
stimulation of nociceptive afferents, inhibition of neurotransmitter release and 
inhibition of other factors, e.g. hormones. Adenosine also protects tissues from 
ischemic damage in e.g., brain and heart (Lasley et al, 1990; Rudolphi et al, 1992; 
Fredholm et al, 1996).   
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Adenosine can be generated both intra- and extracellulary. Adenosine is synthesized 
intracellulary through two separate pathways, through the hydrolysis of AMP to 
adenosine by 5´-nucleotidase (Schubert et al., 1979; Zimmermann et al., 1998), and 
through catabolism of S-adenosylhomocystein (Broch and Ueland, 1980). Adenosine 
can either be released directly into the extracellular compartment or be generated 
from a precursor, ATP, ADP, AMP or camp through the action of ecto-5´-
nucleosidases found on the surface of the cell membrane (Zimmermann et al., 2000).  
 
1.4.2. Adenosine receptors 
 
The actions of adenosine are mediated through four receptors subtypes, A1-, A2A-, 
A2B- and A3-AR (Fredholm et al., 2001). 
 
 
 
 
 
Fig.1.7: Adenosine receptor coupling (www.aderis.com/science/programs.htm). 
 
Adenosine receptors (ARs) are members of the GPCR superfamily. The adenosine 
A1-receptor (A1AR) and A3-receptor (A3AR) are coupled to inhibitory Gi-proteins, 
which inhibit adenylyl cyclase, causing decreases of cAMP and through simulating 
phospholipase C and thereby increasing IP3. The adenosine A2AAR and A2BAR 
receptors are coupled to stimulatory Gs-proteins, which stimulate adenylyl cyclase, 
causing an increase of cAMP. 
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  Effect of Receptor Activation 
 
       
       
A1AR  
Heart Rhythm- 
decrease in heart 
rate, force of atrial 
contraction, and 
responsiveness to 
adrenaline 
 
Wakefulness- 
decrease in electrical 
excitability and 
inhibition of 
excitatory amino acid 
(EAA) release  
Anti-diuresis 
Anti-lipolytic 
Insulin enhancer 
Antihypertensive 
Wound healing 
Hair growth 
 
A2A AR  
Regulates blood 
vessel tone - dilation 
of the coronary 
arteries supplying 
blood to the heart 
muscle 
 
Anti-inflammatory -
cerebral blood flow 
increase 
  Wound healing 
 
A2B AR         
Allergic Responses
GI Tract Relaxation
Anti-inflammatory 
 
A3 AR  Cardioprotective       Allergic Responses
 
Fig.1.8: Physiological effects of adenosine receptors (www.aderis.com/science/programs.htm). 
 
Adenosine acts at the A1AR receptor subtype to cause decreases in heart rate, force 
of contraction, and responsiveness to adrenaline. In the central nervous system, 
adenosine, released during episodes of epilepsy or as a consequence of hypoxia or 
stroke, acts at the A1AR receptor subtype to exert a neuroprotective action by 
decreasing electrical excitability, inhibiting the release of excitatory amino acids. 
A1AR plays role also in mediating endogenous antinociception (Fredholm et al, 2001, 
Dunwiddie et al, 2000). 
A2AAR receptors play a role in mediating pain via peripheral sites, inhibiting platelet 
aggregation and regulating blood pressure (Ledent et al, 1997). A2AAR antagonists 
might be useful as adjuvants to dopaminergic drugs in Parkinson´s desease 
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(Fredholm et al, 1996). A2AAR subtype causes also dilation of coronary arteries to 
enhance blood flow to the heart. 
Accordingly, it is thought that A2BAR play a more important role under 
pathophysiological conditions when interstitial adenosine concentrations are 
markedly elevated. In non-rodent species including humans, the A2BAR receptor is 
expressed in inflammatory cells such as mast cells and activation of this receptor 
causes the release of numerous pro-inflammatory mediators. It has been speculated 
that A2BAR receptors may play an important role in lung inflammation including 
asthma.   
The A3AR is a very unique subtype of adenosine receptor in several respects. Most 
notably, its tissue/cellular distribution, binding properties, and physiological functions 
all differ markedly among species. A3AR receptor causes decrease of mast cell 
degranulation (Salvatore, 2000) and a consequent decrease in vascular permeability 
(Tilley, 2000).  
 
1.4.3. Adenosine receptors in the kidney 
 
In the kidney, adenosine plays an important role in water-electrolyte metabolism, 
such as in the glomerular filtration rate, renal blood flow, renin release, 
tubuloglomerular feedback, tubular sodium and water transport, and neurotransmitter 
release (McCoy et al., 1993). 
Expression in rat renal cortical and medullary tissue has been shown for all four 
adenosine receptors at both the mRNA and protein levels. A1AR expression was 
found in preglomerular vessels, in the juxtaglomerular apparatus, in the medullary 
collecting duct, and in descending vasa recta of the outer medulla. A2AAR appear to 
be mainly associated with renal blood vessels, A2BAR was found predominantly in 
cortical tubular structures. Although A3AR mRNA was detected in whole kidney, the 
A3AR-mRNA was not found in any nephron segment (Vitzhum et al, 2004).  
In most blood vessels, adenosine elicits marked vasodilatation, and this effect is 
mediated by A2A- and A2B-AR. In the renal vasculature, in contrast, adenosine can 
produce vasoconstriction, a response that has been suggested to be an organ- 
specific version of metabolic control designed to restrict organ perfusion when 
transport work increases. Vasoconstriction is a response to activation of high-affinity 
A1AR. A2AR-mediated vasorelaxation is probably facilitated by endothelial receptors 
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that cause the release of nitric oxide and other endothelial relaxing factors (Vitzhum 
et al, 2004). 
Adenosine affects rennin secretion from juxtaglomerular cells and is considered to be 
a signalling molecule for the tubular glomerular feedback. Moreover, adenosine 
influences tubular feedback and A1AR antagonists may serve as potent, natriuretic, 
and potassium-sparing diuretics. In the collecting duct, adenosine antagonizes the 
effect of arginine vasopressine. Accumulating evidence, also, suggests that 
adenosine may also antagonize detrimental inflammatory events in the course of 
ischemic renal failure (Vitzhum et al, 2004).  
 
1.4.4. Adenosine in the heart 
 
The heart possesses a range of retaliatory mechanisms designed to provide 
resistance to injurious stimuli. Of these, considerable evidence points to an important 
role of the adenosine system. The ARs were attributed with regulatory functions in 
the heart and vessels. Recent data indicate that adenosine is an endogenous 
determinant of myocardial ischemic tolerance (Ely et al, 1992; Zhao et al, 1993; Peart 
et al, 2000).  
Adenosine also enhances tolerance to ischemia via metabolic substrate effects. 
Adenosinergic cardioprotection in ischemic-reperfused hearts involves reduction of 
oncotic and apoptotic death, and improved functional outcomes (Peart et al, 2003, 
Regan et al, 2003). Adenosine appears to directly protect cardiomyocytes or 
myocardial tissue, and additionally protects via limiting inflammatory cells and 
vascular and myocardial tissue (Narayan et al, 2001; Vinten-Johansen et al, 1999).  
Endogenous adenosine may protect via one or all of the four characterized AR sub-
types, A1-,A2A-, A2B-, and A3-ARs. All are considered to be expressed in 
cardiovascular cells. Cardioprotective role of A1AR have been supported in vitro and 
in vivo (Peart et al, 2000), and for A2AARs in vivo (Zhao et al, 1993). Protective  
A2AARs effects involve modulation of vascular function, platelet adhesion and 
neutrophil activation (Zhao et al, 1993).  A3AR over-expression enhances tolerance, 
implying an intrinsic function in cardioprotection (Liang et al, 1998; Black et al, 2002). 
A3AR is less sensitive to adenosine than A1AR. Thus, A1ARs will be intrinsically 
activated to a greater extent than A3ARs during ischemia.    
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1.4.5. Adenosine receptors and salt diet 
 
 
The putative role of adenosine in the salt-dependent regulation of the rennin system 
is underlined by several studies suggesting a relationship between tubular salt load 
and adenosine concentration in the kidney.  Infusion of hypertonic saline or a high 
dietary sodium intake, both of which are associated with an inhibition of the rennin 
system, led to elevated adenosine concentrations in the kidney. In contrast, dietary 
sodium restriction, known to stimulate the rennin system, resulted in reduced renal 
interstitial concentrations of adenosine. Therefore, an increase in adenosine 
concentrations due to a high tubular salt load could mediate vasoconstriction and 
inhibition of the rennin system, whereas a decrease in renal adenosine 
concentrations resulting  from a reduced salt load could cause vasodilatation and 
stimulation of the renin system (Zou et al, 1999).  
High salt diet causes down-regulation of A1AR, does not alter A2A- and A2B-AR and 
up-regulates A3AR in both renal cortex and medulla (Zou et al, 1999).  
The effect of salt on heart adenosine receptor expression was not investigated until 
now.  
 
1.5. NITRIC OXIDE (NO) 
 
A gaseous nitrogen monoxide radical, nitric oxide (NO), is a ubiquitous signalling 
molecule able to diffuse readily across cell membranes. Its biological effects are 
mediated through a variety of intracellular and extracellular proteins and it may also 
exist as a second messenger. NO is modulating bride range of physiological 
responses including gene regulation, cytostasis, apoptosis, platelet function, vascular 
smooth muscle cell relaxation and proliferation, neurotransmission, memory, and 
immune stimulation (Ignarro et al., 1999; Loscalzo et al., 2000, Murad et al., 1998). 
Unregulated production of NO can cause nitrosative stress, leading to damages of 
proteins/DNA and to cell injury and death (Murphy et al., 1999).  
 
1.5.1. Synthesis of NO 
 
Synthesis of this seemingly most simple molecule involves one of the most 
complicated enzymes in nature, the nitric oxide synthase (NOS), which contains 
several cofactors and is highly regulated (Nathan et al, 1994).  
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Fig.1.9: Nitric oxyde biosynthesis. NOS catalyzes the oxidation of L-arginine to L-citrulline and •NO. 
Molecular oxygen and NADPH are co-substrates in this reaction. The first step in this reaction is the 
N-hydroxylation of L-arginine, yielding NG-hydroxy-L-arginine (L-NHA, shown as the oxime) as an 
intermediate. L-NHA is further oxidized to L-citrulline and •NO in an NADPH- and O2-dependent step. 
 
1.5.2. Nitric oxide signalling 
 
The classical physiological role of NO generally reflects direct activation of guanylate 
cyclase to generate cGMP, followed by kinase-mediated signal transcduction 
(Ignarro et al., 1999; Loscalzo et al., 2000). However, several other NO-related 
activities are cGMP-independent.  
 
 
 
 
Fig.1.10: Role of cGMP in mediating the biological effects of nitric oxide. 
(www.merckbiosciences.co.uk/html/cbc/cellular_signaling_with_nitric_oxide.htm). 
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1.5.3. Nitric oxide synthase (NOS) 
 
NOS is known to exist in three isoforms: endothelial, inducible and neuronal NOS.  
Endothelial (eNOS or NOS III) and neuronal (nNOS or NOS I) isoforms are so 
labelled because they were initially identified in endothelial cells and neurons, 
although they have subsequently been identified in many different cell types. Both 
are expressed constitutively and activated by Ca2+. Inducible NOS (iNOS or NOS II) 
was first identified in macrophages but its expression can be induced in almost all 
cell type. These three isoforms are encoded by different genes, exhibit similarities in 
their structure (60% structural homology) as well as in their action. Calmodulin is 
required for the activity of all three isoforms. The constitutive eNOS and nNOS have 
an absolute requirement for Ca2+ and calmodulin; therefore, Ca2+ plays a critical role 
in •NO signal transduction. iNOS, on the other hand, binds calmodulin tightly and is 
not regulated by Ca2+. 
All three NOS isoforms are subject to transcriptional controls. As originally identified, 
eNOS and nNOS were believed to be only constitutively expressed in their 
characteristic tissues, whereas expression of iNOS was inducible upon 
immunoactivation, for example, in response to LPS, interferon γ, TNF-α, and IL-1. 
However, nNOS is known to be upregulated in diverse tissue models, including 
cutaneous wound repair and ischemic preconditioning (10,11). Similarly, eNOS 
transcription can be actively modulated in endothelial cells, for example, in response 
to laminar shear stress (Dekker et al, 2002; Sen Banerjee et al., 2004). 
 
1.5.4. The role of NO in the regulation of the kidney 
 
The free radical nitric oxide (NO) has been shown to play an important role in various 
physiological processes in the kidney, including salt and fluid reabsorption (Kone et 
al., 1997), renal hemodynamics (Kurtz et al., 2000), rennin secretion (Kurtz et al., 
1998) and tubuloglomerular feedback (Ren et al, 2000). Additionally NO may have a 
dual role in several diseases states of the kidney such as renal acute failure, 
inflammatory nephritides, diabetic nephropathy and transplant rejection. 
Several recent studies have demonstrated that nitric oxide directly affects tubular 
sodium transport and may be an important mediator of the changes induced by 
arterial pressure in sodium excretion, as described in Fig.1.6 (Navar et al., 1996; 
Stoos et al., 1995). Increases in arterioral shear stress caused by increases in 
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arterial pressure stimulate production of NO. NO may exert direct effects to inhibit 
tubule sodium reabsorptive mechanisms and may elicit vasodilatory actions. NO 
increases intracellular cyclic GMP (cGMP) in tubular cells, which leads to a reduced 
reabsorption rate through cGMP-sensitive sodium entry pathways (Stoos et al, 1994; 
Stoos et al, 1995). When formation of nitric oxide is blocked by agents that prevent 
nitric oxide synthase activity, sodium excretion is reduced and the pressure 
natriuresis relationship is markedly suppressed (Schnackenberger et al., 1997; 
Mattson et al., 2000). Thus, nitric oxide may exert a critical role in the regulation of 
arterial pressure by influencing vascular tone throughout the cardiovascular system 
and by serving as a mediator of the changes induced by the arterial pressure in 
tubular sodium reabsorption. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.11: Nitric oxide in mediation of pressure natriuresis (Navar et al., 2004). 
 
FUNCTIONS OF NO IN THE KIDNEY 
1. Renal macrovascular and microvascular dilatation (afferent > efferent) 
2. Regulation of mitochondrial respiration 
3. Modulation renal medullary blood flow 
4. Stimulation of fluid, sodium and HCO3- reabsorption in the proximal tubule 
5. Stimulation of renal acidification in proximal tubule by stimulation of cellular Na+-H+ exchangers 
activity 
6. Inhibition of Na+, Cl- and HCO3- reabsorption in the thick ascending loop of Henle 
7. Inhibition of Na+, conductance in the cortical collecting duct 
8. Inhibition of H+-ATPase in  the cortical collecting duct 
 
Tab. 1.3: Functions of NO in the kidney (Sharma, 2004).  
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All three NOS isoformes are differentially expressed throughout the kidney. A 
constitutive, neuronal NOS (nNOS), is heavily expressed in macula densa cells, 
where it functions to blunt the expression of the TGF response (Wilcox et al., 1996) 
and to regulate rennin secretion (Beierwaltes, 1995). Immunohistochemical studies 
have shown that some nNOS is also expressed in Bowman´s capsle, some cells of 
the thick ascending limb or collecting ducts, efferent arteriole cells and certain renal 
nerves (Bachmann et al, 1995). Endothelial NOS is abundantly expressed in renal 
microvasculature, glomerular endothelial cells, proximal tubular cells, thick ascending 
of Henle´s loop and collecting tubule (Ujiie et al., 1994). Functional studies support 
the presence of iNOS in proximal tubule and in vitro studies in cultured cells indicate 
the presence of iNOS in glomerular mesangial and inner medullary collecting duct 
cells (Mohupt et al., 1994), although the exact localisation of iNOS in vivo is still 
unclear.  
Endogenous NO derived from nNOS and iNOS mediate the natriuresis in the 
proximal tubule as demonstrated by studies from knockout models and specific 
inhibitors of nNOS and iNOS. There is no evidence that supports the role of eNOS in 
directly modulating proximal tubular transport (Sharma, 2004).  
 
1.5.5. NOS in the hearth 
 
nNOS and eNOS are both found in the normal hearth in a restricted distribution: 
nNOS primarily in nerves innervating the hearth but also in the sarcoplasmic 
reticulum of cardiomyocytes, eNOS constitutively expressed in the endocardial and 
vascular endothelium as well as in cardiomyocytes, albeit at much lower 
concentrations. In contrast, iNOS may be expressed in all cell types in response to 
an adequate stimulus. This complex distribution of NOS isoforms is matched by the 
variety and complexity of the cardiac effects attributed to NO (Arnolda, 2002). 
In cardiovascular  system, NO generation from endothelium is important to maintain 
the vasculature in a relaxed state, inhibit the adhesion of platelets and white cells and 
suppress the replication of smooth-muscle cells (Napoli and Ignarro, 2001). 
Pharmacological inhibition of NOS causes vasoconstriction, hypertension and 
enhanced platelet activation, and increases atherogenesis in animal models (Cayatte 
et al., 1994). In addition, eNOS knockout mice  are hypertensive, show exaggerated 
smooth-muscle replicative responses to vascular injury, are more prone to 
atherogenesis  and develop aneurysms (Kuhlencordt et al., 1001). eNOS is also 
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important to promote angiogenesis and regulate the expression of vascular-
endothelial growth factor. So, prolonged inhibition of eNOS activity is considered 
detrimental.  
In the heart, nNOS and eNOS seem to have different and sometimes opposing 
effects (Barouch et al., 2002). NO derived from nNOS has a positive ionotropic 
response, possibly secondary to activation of sarcoplasmic-reticulum calcium 
release, whereas eNOS activity decreases β-adrenoreceptor-induced contractility 
through effects on L-type calcium channels (De Sanctis et al., 1999).  
Expression of iNOS has been implicated as a key mediator of ischemic 
preconditioning in the heart (Nandagopal et al., 2002). Once expressed, it generates 
large amounts of NO, and its activity is not dependent on intracellular calcium. 
Congestive heart failure results in myocardial iNOS expression and excessive NO 
production, leading to deterioration of contraction and impairment of relaxation. It is 
suggested that iNOS plays an important role in the transition from compensated 
hypertrophy to failure in Dahl salt-sensitive hypertensive heart failure model 
(Horinaka et al., 2003). 
 
1.5.6. Influence of high salt/sodium-retaining steroid hormones diet on NO and 
NOS 
 
Several data indicate that NOS plays an important role in the regulation of sodium 
and water homeostasis during increases in dietary salt intake. Recent studies have 
shown that increase in salt intake cause a variable response of NOS proteins in the 
kidney. Mattson and Higgins, 1996 reported, that high salt diet increased the levels of 
eNOS, iNOS and nNOS in renal medulla of Sprague-Dawley (SD) rats. The authors 
think, that the increased NOS levels may be important in the chronic adaptation to a 
high salt diet. This observation is consistent with increased urinary nitrate and nitrite 
excretion in normotensive rats placed on a high salt diet (Schultz and Tolins, 1993; 
Tolins and Schulz, 1994), which indicates that in vivo NO activity is increased  when 
rats are maintained on an elevated sodium intake.  
In contrast, Ni and Vazari, 2001 reported that the consumption of high salt diet for 
three weeks induced hypertension and downregulation of iNOS, eNOS and nNOS in 
SD rats. The decreased iNOS expression  was found in renal cortex, renal medulla, 
aorta, and heart. Similarly, chronic salt loading resulted in marked downregulation of 
eNOS expression in renal cortex and aorta and lowered expression of nNOS in the 
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brain, renal cortex, and renal medulla. In comparison, short-term loading  resulted in 
significant elevation of nNOS expression in renal medulla and brain. 
Further experiments with high salt diet were done with Dahl salt-sensitive and Dahl 
salt-resistant rats. The authors reported that the renal meddulary iNOS proteins 
increased in Dahl salt-resistant rats and did not significantly change in Dahl-salt-
sensitive rats  after 1-week exposure to high salt diet.  
Jin et al, 2003 demonstrated, that direct perfusion of the hypothalamic 
paraventricular nucleus region with hypertonic saline elicits a local release of NO, 
which may be carried out by activating nitric oxide synthase to produce 
cardiovascular responses. 
Studies in animals and humans indicate that the hormone aldosterone impairs NOS 
activity. Patients with primary hyperaldosteronism exhibit a greater degree of 
endothelial dysfunction that do patients with essential hypertension (Taddei et al., 
1993). Tae-Yon et al, 2003 showed that aldosterone decreased NO production by 
iNOS and spironolactone increased iNOS expression in neonatal rat cardiomyocytes. 
The effect of aldosterone to reduce iNOS expression could under certain conditions 
lower NO to where it would result in a loss of optimal cardiac function, whereas 
spironolactone would restore function. There is at least one human study where an 
aldosterone antagonist appeared to increase bioavailable NO (Furquharson, 2000). 
Aldosterone mediated inhibition of iNOS could aggravate cardiac function under 
conditions such as occur with heart failure.  
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2. AIMS 
 
A. All four systems, the adenosine-, nitric oxide and nitric oxide synthases, KKS and 
RAAS are important for blood pressure regulation, sodium and extracellular fluid 
volume balance. All of these systems are individually very well examined but the 
interactions between these systems are still not entirely clear. The aim of this work 
was to characterize the interaction between the KKS, adenosine system, NOS and 
aldosterone in the kidney and heart of rat. 
 
We have focused on: 
 
? Effect of high salt diet and spironolactone administration on the NOx level in 
plasma and urine of kininogen-deficient BNK rats and their wild-type BN rats 
under standard diet.  
? The expression of adenosine receptors (A1-, A2A-, A2B-, A3-AR), NO synthases 
(eNOS, iNOS, nNOS) and bradykinin receptors (B2R, B1R) in the kidney and heart 
of kininogen-deficient BNK rats and their wild-type BN rats under standard diet.  
? The effect of high salt diet on the expression of adenosine receptors (A1-, A2A-, 
A2B-, A3-AR), NO synthases (eNOS, iNOS, nNOS) and bradykinin receptors (B2R, 
B1R) in the kidney and heart of BNK and BN rats. 
? The effect of spironolactone (aldosterone antagonist) on the expression of 
adenosine receptors (A1-, A2A-, A2B-, A3-AR), NO synthases (eNOS, iNOS, nNOS) 
and bradykinin receptors (B2R, B1R) in the kidney and heart of BNK and BN rats. 
? The effect of high salt diet in combination with spironolactone treatment on the 
expression of adenosine receptors (A1-, A2A-, A2B-, A3-AR), NO synthases (eNOS, 
iNOS, nNOS) and bradykinin receptors (B2R, B1R) in the kidney and heart of BNK 
and BN rats. 
  
B. In the second part of the dissertation we have focused on the concentration-
response relationship of kinin signalling on the B1R and B2R by using measurement 
of intracellular calcium levels in the cell lines expressing B1R/B2R of human, mouse, 
and rat. 
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3. MATERIAL AND METHODS 
 
3.1. MATERIAL 
 
3.1.1. Experimental Animals 
 
Brown-Norway (BN) rats, males, 200-250g       (Charles River laboratories, Sulzfeld, GE) 
Brown-Norway Katholiek (BNK) rats, 
males, 200-250g        (University of Kiel)         
Standard diet (0,5% NaCl)     (Altromin, Lage) 
High salt diet (5% NaCl)     (Altromin, Lage) 
 
3.1.2. Material 
 
Beakers       (Brand, Wertheim, GE)      
Biozym Pipette 20-200µl                                   (Biozym, Hessig Oldendorf, GE) 
Dishes      (Becton Dickinson Labware, USA) 
Eppendorf pipettes     (Eppendorf, Hamburg, GE) 
Eppendorf tubes 1.5ml, 2ml, 0.5 ml  (Eppendorf, Hamburg, GE) 
Falcon tubes 15 ml, 50 ml    (Becton Dickinson Labware, USA) 
Gel casting platform     (Peqlab biotechnologieGmBH, GE) 
Gel combs (slot formers)    (Peqlab biotechnologie GmBH, GE) 
Glass cylinders      (Brand, Wertheim, GE) 
Ligh Cycler Capillaries    (Roche, Mannheim, GE) 
Ligh Cycler cooling block    (Roche, Mannheim, GE) 
Micro dispossable cuvettes   (Ratiolab, Dreieich, GE) 
Microscop cover glass    (Hartenstein, GE) 
Needle 27G, 20mm     (Braun, Melsungen, GE)   
Pipette tips       (Brand, Wertheim, GE) 
Rat operation table     (University of Heidelberg, GE) 
Scalpel       (Rosifrei, GE) 
Sterile pipette 2.5ml, 5ml, 10ml, 25ml  (Sarstedt, Nümbrecht, GE) 
Surgical tools 
Syringe1 ml         (Becton Dickinson Labware, USA) 
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3.1.3.  Instruments 
 
Analytical balance      (Sartorius, Göttingen, GE) 
Balances       (Sartorius, Göttingen, GE) 
Bio Photometer      (Eppendorf, Hamburg, GE) 
Camera Sensi Cam CCD    (PCO AG, USA) 
Centrifuge        (Eppendorf, Hamburg, GE) 
Concentrator 5301      (Eppendorf, Hamburg, GE) 
Gel Doc 2000 system     (BioRad, Munich, GE) 
Horizontal gel electrophoresis apparatus  (Biorad, Munich, GE) 
Laminar Flow Cabinet    (Heraus, GE) 
LKB-2002 Power supply    (Bromma, Schweden)  
Ligh Cycler System 1.0     (Roche, Mannheim, GE)   
Magnetic Mixer      (Heidolph, type MR 3001 K, GE) 
Magnetic Mixer      (Variomag, GE) 
Microskope Zeiss Axiovert 135   (Hitachi, USA) 
Microwave heater      (Panasonic, GE) 
NanoDrop ND1000 Spectrophotometer  (Biozym, Hessig Oldendorf, GE) 
Owen WTB, Model 1511530000202  (Binder, GE) 
PH-Meter, Model 766    (Knick, GE) 
Speed Vac, Model SC110 220   (Savant, USA) 
Spectrofluorophotometer    (Schimadzu, Duisburg, GE) 
Thermal Cycler      (Roth, Karlsruhe, GE) 
Test tube thermostat TCR 100   (Carl Roth, Karlsruhe, GE) 
Refrigerators 4oC, -20 oC, -80 oC    (Liebherr Premium,GE) 
Ultrasonic bath, Bandelin Sonorex RK 102P (Schalltec, Mörfelden-Wall, GE) 
Ultra Turrax TP 18-10    (IKA Werk, Staufen, GE) 
Vortex       (Heidolph genie 2, Heidelberg, GE)  
Water bath       (Eppendorf, Hamburg, GE) 
 
3.1.4. Chemicals 
 
Acetic acid      (J.T.Baker, Deventer, Holland) 
Agarose ultrapure     (GibcoBRL, GE) 
Bradykinin      (Bachem, Weil am Rhein, Germany) 
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Calcium chloride      (AppliChem, Darmstadt, GE) 
dATP       (Promega, Mannheim, GE) 
dCTP       (Promega, Mannheim, GE) 
des-Arg9-BK      (Bachem, Weil am Rhein, Germany) 
des-Arg10-KAL     (Bachem, Weil am Rhein, Germany) 
des-Arg10LP      Bachem, Weil am Rhein, Germany) 
DNA Molecular Weight Marker                            (Bioline, GE) 
DEPC       (Roth, Karlsruhe) 
dGTP       (Promega, Mannheim, GE) 
D-MEM medium     (GibcoBRL, GE) 
DMSO (dimethylsulfoxid)    (Sigma, Deisenhofen, GE) 
DNA Loading Dye 6x    (Fermentas, St.Leon-Roth, GE) 
DNA-OFF      (ApplyChem, GE) 
D-PBS       (GibcoBRL, GE) 
dTTP       (Promega, Mannheim, GE) 
EDTA       (Roth, Karlsruhe) 
Ethanol absolute     (Riedel-de Haen, Hannover, GE) 
Ethidium bromide     (GibcoBRL, GE) 
Fetal bovine serum (FBS)    (GibcoBRL, GE) 
Fura-2/AM       (Molecular Probes, Invitrogen, GE) 
Glucose      (AppliChem, Darmstadt, GE) 
99.9% Glycerol      (J.T.Baker, Deventer, Holland) 
HBSS medium     (GibcoBRL, GE) 
Hydrochloric acid     (Merc, Darmstadt, GE) 
Isopropanol       (JT Baker, Deventer, Holland) 
Kallidin       Bachem, Weil am Rhein, Germany) 
Kallidin-like-peptide     (Bachem, Weil am Rhein, Germany) 
L-Glutamin      (GibcoBRL, GE) 
Liquid nitrogen      (Theoreticum, University of Heidelberg) 
Magnesium chloride    (Merck, Darmstadt, GE) 
Β-merkaproethanol     (Acros Organics, USA) 
MOPS      (Serva, Heidelberg,GE) 
10 mM d NTP´s      (Peqlab, GE) 
Olive oil      (Sigma, Diesenhofen, GE) 
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Penicillin/Streptomycin    (GibcoBRL, GE) 
Pwo polymerase; concentration 1U/µ l   (Promega, USA) 
RNAse ZAP      (Sigma, Diesenhofen, GE) 
RNA Later       (Ambion, GB) 
RNA-sample loading buffer R 4268   (Sigma, Diesenhofen, GE) 
Smart Ladder marker 200-10 000bp   (Eurogentec, GE) 
Sodium chloride     (Merc, Darmstadt, GE) 
Sodium dodecylsulfate    (Merc, Darmstadt, GE) 
Sodium hydroxid     (Merck, Darmstadt, GE)  
Spironolactone     (Sigma, Diesenhofen, GE) 
Taq polymerase; concentration 5U/µ l   (Promega, USA) 
Tris        (Roth, Karlsruhe) 
Trypsin      (GibcoBRL, GE) 
 
3.1.5. Kits 
 
Fast Start DNA Master SYBR Green 1  (Roche, Mannheim, GE) 
Nitric oxide assay Kit, fluorimetric  (Calbiochem, GE) 
Quanti Tect Riverse Transcription Kit   (Qiagen, GE) 
Rneasy Kit       (Qiagen, GE) 
 
3.1.6. Cell lines 
 
Flp-In T-REx 293 cell lines stably expressing gene for B1R-(rat, mouse, human) or 
B2R -(rat, mouse, human) receptor. The Flp-On T-Rex-293 cell line is derived from 
293 human embryonic kidney cells (293 HEK). The cell lines were obtained from 
Prof. A.Faussner, Munich.   
 
3.1.7. Primers  
 
Primers for this study were synthesized from Invitrogen. 
 
Rat PBGD forward Primer reverse Primer 
Labelling of the Primer PBGD 1.1 PBGD 1.2 
Sequence gga gtt cag tgc cat tat cct ggc gca aca cac cca cta ggt cca ag 
Melting temperature 74 72 
Position (bp) in X06827 547 697 
Product size  150 bp 
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Rat  A1AR forward Primer reverse Primer 
Labelling of the Primer A1 2.1 A1 2.2 
Sequence tta ctg tct ggg gca cca agc t cac act gaa gac agc agt ctc 
Melting temperature 70 64 
Position (bp) in NM_017155 1081 1280 
Product size  199 bp 
   
Rat A2A-AR forward Primer reverse Primer 
Labelling of the Primer A2A-AR 1.1 A2A-AR 1.2  
Sequence tct tgg gct agc ccavagc tac c tca tgg gac ctg agc cca tgc 
Melting temperature 70 68 
Position (bp) in NM_053294 2199 2299 
Product size  100 bp 
   
Rat A2B-AR forward Primer reverse Primer 
Labelling of the Primer A2B-AR 2.1 A2B-AR 2.2 
Sequence ccg tgc atg  cca tca  act gc Aca act gaa ttg gcg tgt gac a 
Melting temperature 64 64 
Position (bp) in NM_017161 792 879 
Product size  87 bp 
   
Rat A3AR forward Primer reverse Primer 
Labelling of the Primer A3 1.1 A3 1.2 
Sequence gtg gtc ggc ttg gat tac atg cca gca caa ggc aaa caa gaa gag 
Melting temperature 64 72 
Position (bp) in NM_013168 999 1197 
Product size  198 bp 
   
Rat iNOS forward Primer reverse Primer 
Labelling of the Primer iNOS 2.1 iNOS 2.2 
Sequence gga gtt cag tgc cat tat cct ggc gca aca cac cca cta ggt cca ag 
Melting temperature 74 72 
Position (bp) in NM_012611 2279 2478 
Product size  199 bp 
 
Rat eNOS forward Primer reverse Primer 
Labelling of the Primer eNOS 2.1 eNOS 2.2 
Sequence gga gtt cag tgc cat tat cct ggc gca aca cac cca cta ggt cca ag 
Melting temperature 74 72 
Position (bp) in NM_021838 1318 1517 
Product size  199 bp 
   
Rat nNOS forward Primer reverse Primer 
Labelling of the Primer nNOS 1.1 nNOS 1.2 
Sequence agg ccg tca agt tct cag cca a caa agg tgc tgg tga cca cca a 
Melting temperature 68 68 
Position (bp) in NM_052799 2307 2507 
Product size  200 bp 
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Rat B1R forward Primer reverse Primer 
Labelling of the Primer B1F1 B1R1 
Sequence  agg taa gag tga tcc agg act  tgg aag agt ccc ttc ctg ttg 
Melting temperature 59.506 59.75 
Position (bp) in Bdkrb B1 884 1073 
Product size  190 bp 
 
Rat B2R forward Primer reverse Primer 
Labelling of the Primer B2F1 B2R1 
Sequence tgc tga gga aca acg aga tga cgt agg ac tga tct ggg tga 
Melting temperature 59.63 59,35 
Position (bp) in Bdkrb B2 884 1094 
Product size  189 bp 
 
 
3.1.8. Software 
 
• Gel Doc       (Biorad, Munich, GE) 
• GeneFisher, interactive PCR primer design  (University of Bielefeld, GE) 
• GradPadPrism 4       (GraphPad Software, USA) 
• Ligh Cycler Software-version 3.5    (Roche, Mannheim, GE) 
• Microsoft Office-Word, Excel, Internet Explorer (Microsoft, USA) 
• ND-1000 V3.1.0                                                  (Nanodrop, USA) 
• REST software      (Technical University, Munich) 
• TILLvisION software-version 4.00   (TILL Photonics) 
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3.2. METHODS 
 
3.2.1. Animal experiment 
 
All experiments were performed in accordance with FELASA guidelines for animal 
experimentation. 
Male Brown-Norway (BN) and kininogen deficient Brown-Norway-Katholiek (BNK) 
rats of 300-350g were used throughout the study.  The animals were housed under 
controlled laboratory conditions, with a standard 12h day/night cycle. 
Animals of each strain were randomly divided into four experimental groups and 
underwent following treatment for 10 days: standard salt diet (0.5% NaCl) 
±spironolactone (20mg/day s.c) or high salt diet (5% NaCl, Atromin) ±spironolactone 
for 10 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.1: Scheme of the animal experiment. 
 
 
Spironolactone (100mg) was suspended in 1ml of olive oil. Rats received a 
subcutaneous injection of 200µl of spironolactone per day. On the 9th day the rats 
were put in metabolic cages for 24 h and the urine was collected into urine collection 
tubes that were cooled with an ice bath. The tubes as well as the lower part of 
metabolic cages were treated with silicone solution to avoid loss of fluid and peptide 
adsorption. Urine was than centrifuged (6000rpm, 15 min at 4oC) to remove food 
contamination. Aliquots of urine were stored at -20oC until use.  
On the 11th day rats were anaesthetized (pentobarbital 60mg/kg i.p.). The blood was 
collected from carotid artery into pre-chilled siliconized plastic tube with 1ml 3.8% 
sodium citrate. The blood was than properly mixed with the citrate to prevent 
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coagulation and centrifuged (6000 rpm, 10 min at 4oC). Plasma supernatant was 
aliquoted and stored at –20oC until used.  Finally the organs (atria, ventricles, kidney, 
liver) were isolated and stored in RNAlater at –20oC. 
 
3.2.2. RNA stabilisation 
 
Tissue samples were submerged in an appropriate volume of  RNA later immediately  
after harvesting. RNAlater solution mainly consists out of EDTA (20mM), sodium 
citrate (25mM) and high concentrated ammonium sulfate (700g/L) which denatures 
proteins and so prevents RNA-degradation by ribonucleases (RNases). Importantly, 
cellular structure remains intact. Sample stabilisation and RNA protection ensure 
reliable gene expression analysis. To ensure absolute permeation of RNAlater 
through tissue, the samples were incubate in RNAlater first overnight at 4oC and then 
transferred to –20oC for archival storage.  
 
3.2.3. RNA Isolation 
 
 
Total RNA was isolated from atria, ventricles and kidney using a commercially 
available kit (Rneasy Kit, Qiagen) under protocol for Total RNA isolation from animal 
tissue. 
Approximately 30mg of tissue sample was used for the total RNA isolation. The 
organ was placed in glass vessel containing 600µl lysis buffer RLT and 6µl β-
mercaptoethanol and the sample was homogenized with rotor-stator homogenizer 
(Ultra Turax) until the sample was uniformly homogeneous (60 s). The sample was 
further homogenized by passing lysate at least 5 times through a 20-gauge needle 
fitted to an Rnase-free syringe.  
Subsequently 1180µl of sterile water and 40µl (20mg/ml) of Proteinase K were added 
to the sample. The  samples were incubated at 55oC for 10 min.  
After incubation the samples were placed in 2ml tube and centrifuged for 3 min at 
13000rpm. The supernatant was collected in a 15ml Falcon tube and 1800µl of 
ethanol absolute was added. The sample was mixed by pipetting. Subsequently 
700µl of the sample was applied to a column placed in a 2ml collection tube. The 
sample was centrifuged for 15 s at 10000rpm and the flow-through was discarded. 
The aliquots of the sample were successively loaded onto the column and 
centrifuged as above. Then 350µl of wash buffer RW1 was added and the tube was 
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centrifuged for 15 s at 10000rpm and the flow-through was discarded. Subsequently 
500µl of buffer RPE were added twice, centrifuged for 15 s at 10 000rpm and the 
flow-through was discarded. After this step the tubes were centrifuged for another 2 
min at 10 000rpm and the flow-through was discard. For elution the columns were 
placed into a new 1.5 ml collection tube and 70µl of Rnase-free water was pipetted 
directly onto the silica-gel membrane of the column. Finally the tube was centrifuged 
for 1 min at 10000rpm. The RNA was stored at –80oC. 
 
3.2.4. RNA quantification 
 
Total RNA  concentration was determined by UV-light absorbance using  NanoDrop 
ND1000 Spectrophotometer. This machine measures the extinction by 260 
(absorption maximum for RNA) and the extinction by 280nm (absorption maximum 
for proteins). 
 
Fig.3.2: NanoDrop ND 1000 Spectrophotometer 
 
The RNA concentration was calculated using this formula:  
 
     c(ng/µl) = Extinction by 260nm x 40 (RNA-Multiplication factor)X Dilution factor 
 
The ratio of the reading at 260 and 280 nm (A260/A280nm) provides an estimate of the 
purity of RNA with respect to contaminants that absorb in the UV, such as protein.  
Ratio of A260/A280nm of ~ 2.0  and ratio is generally accepted as pure for  RNA. 
 
The RNA sample (1µl) was measured three times and the overage concentration was 
subsequently calculated.  
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Fig.3.3:  Nucleic acid concentration and quality measurement 
 
 
3.2.5. Control of RNA quality using gelelectrophorese 
 
The integrity and size distribution of total RNA was verified by denaturing agarose gel 
electrophoresis and ethidium bromide staining. The respective ribosomal bands 
should appear as sharp bands on the stained gel. The 28S ribosomal RNA bands 
should be present with an intensity approximately twice that of the 18S rRNA band. If 
the ribosomal bands in a given lane are not sharp, but appear as a smear of smaller 
sized RNAs, it is likely that the RNA sample suffered major degradation during 
preparation.  
To 1.2g of agarose powder 75ml of DEPC H2O was added. Then the agarose was 
melt in a microwave and 10ml of 10X MOPS buffer was added and mixed. When the 
agarose solution was cooled to 60°C, 18ml of formaldehyde (37%) was added and 
mix thoroughly and the gel was poured. 
The RNA sample (1µg) was mixed with loading buffer (1 volume sample to 2 volumes 
of loading buffer). Subsequently the sample was heated to 65oC for 10 min and then 
chilled on ice immediately before loading on the gel. Electrophoresis was run for ~2h, 
at 5V/cm. 
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Fig.3.4: Formaldehyde agarose gel of total RNA.  
 
3.2.6. Reverse transcription  
 
 
For quantification of RNA transcripts, quantitative, real-time RT-PCR is the most 
sensitive and reliable method. RT-PCR begins with reverse transcription of RNA into 
cDNA, and is followed by PCR amplification of the cDNA. RNA is transcribed into 
single-stranded cDNA using random primers, gene-specific primers, or oligo dT 
primers that specifically hybridise to the poly-A tail o mRNAs.  
Reverse transcription (RT) was carried out using 2µg of total RNA from kidney, atria 
and ventricles of each rat using QuantiTect Reverse Transcription Kit (Qiagen). The 
total RNA (2µg) were diluted in Rnase-free water up to 12µl total volume. The RNA 
sample was then briefly incubated in gDNA Wipeout buffer at 42oC for 2 min to 
remove contaminating genomic DNA. After genomic DNA elimination the RT was 
performed at 42oC for 15 min in a total volume of 20µl using 1µl of the Quantiscript 
Reverse Transcriptase, 4µl Quanticript RT buffer and 1ml RT Primer Mix (Optimised 
blend of oligo-dT and random primers dissolved in water). The reaction was then 
inactivated at 95oC for 3 min. cDNA was subsequently diluted 1:10 in sterile water 
and stored in -20 oC. 
 
3.2.7. Primer-Design 
 
The specific sequence of all genes was found in databases NCBI. All primers were 
carefully designed using GeneFisher-Software. 
For efficient amplification in real-time PCR, primers should be designed so that the 
size of the amplicon is ideally < 200bp.  The primer should be 18-24 bases long, 
containing 40-60% G/C, containing no internal secondary structure. The primers 
should not be complementary to each other at the 3´ends to avoid primer-dimer 
forming. Both primers (forward and reverse) should have similar melting temperature. 
28S rRNA 
 
18S rRNA 
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Optimal annealing temperature is usually ~ 5 to 10oC lower than the Tm values of the 
primers and has to be determined empirically.  
Primers for this study were synthesized from Invitrogen. All primers were diluted with 
sterile water to final concentration of 100µM. 
 
3.2.8. Polymerase chain reaction (PCR) 
 
PCR is an in vitro method for enzymatically synthesizing defined sequence of DNA. 
The reaction uses two oligonucleotide primers that hybridise to opposite strands and 
flank the target DNA sequence that is to be amplified. The elongation of the primers 
is catalysed by a heat-stable DNA polymerase. A repetitive series of cycles involving 
template denaturation, primer annealing, and extension of the annealed primers by 
the polymerase results in exponential accumulation of a specific DNA fragment. The 
ends of the fragment are defined by the 5´ends of the primers. The number of target 
DNA copies approximately doubles every cycle, because the primer extension 
products synthesized in a given cycle can serve as a template in the next cycle. 
 
PCR reaction composition: 
o 5µl 10x PCR reaction buffer 
o 1µl forward-Primer (5µM) 
o 1µl reverse-Primer (5µM) 
o 2µl dNTP´s (2.5mM) 
o 0.5µl Taq DNA polymerase 
o 3µl cDNA (1:10) 
o 31.5µl H2O 
 
PCR amplification was performed with synthetic gene-specific primers for adenosine 
A1-, A2A-, A2B-, A3-ARs, eNOS, iNOS and nNOS, bradykinin B1R and B2R for 35 
cycles of denaturation at 95oC for 10s, annealing at 69oC  (PBGD), 66oC (A1AR and 
A3AR) and 60oC (A2AAR, A2BAR, B1R and B2R) for 45s, and elongating at 72oC for 
20s.  
The quality of synthesized cDNA was tested with primers for a rat gene for 
porphobilinogen deaminase (PBGD). PBGD is a housekeeping gene with low 
abundance and constant expression. 
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Fig.3.5: PBGD PCR with cDNA from the kidney of BN rats. 
 
3.2.9. Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis is a simple and highly effective method for separating, 
identifying, and purifying 0.5 to 25-kb DNA fragments.  Nucleic acids contain negative 
charge of phosphoric groups in neutral pH. Thanks to this fact they can move in 
electrical field to positive electrode. DNA molecules are divided in the gel according 
to their size. 
DNA fragments obtained from PCR reaction  were separated on a 1.5% agarose gel 
using 1X TAE buffer.  After heating the agarose and TAE buffer in a microwave, the 
mixture was stirred, until it temperature decreased to ca. 40oC, and ethidium bromide 
was added to the gel for later visualization of the DNA. After running the gel on 1X 
TAE buffer, the bands were visualized using a UV illuminator and Bio-Rad gel 
documentation apparatus (GelDoc2000) accomplished with a camera.  
                                                                                                                                                    
For size determination and quantification of DNA was used Hyper-Ladder Marker – 
200 to 10000bp. The Hyperladder Marker produces a pattern of 14 regularly spaced 
bands, ranging from 200 to 10000bp.  For quantification 5µl of marker was loaded 
and each band correspond to an exact quantity of DNA.    
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3.2.10. Real-Time Quantitative PCR (RT-PCR) 
 
3.2.10.1. Introduction 
 
Reverse transcription (RT) followed by real-time quantitative polymerase chain 
reaction (RT-PCR) is the technique of choice for analysing mRNA in extremely low 
abundance. Because of its high sensitivity, RT-PCR is increasingly used to quantify 
physiologically changes in gene expression. RT-PCR is the technique collecting data 
throughout the PCR process as it occurs, thus combining amplification and detection 
into a single step. This is achieved using fluorescent dye (SYBR Green). SYBR 
Green binds all double-stranded DNA molecules, emitting a fluorescent signal. Signal 
intensity increases with increasing cycle number due to the accumulation of PCR 
product. 
 
 
 
 
 
 
Fig.3.6: At the beginning of amplification, the reaction mixture contains the denatured DNA, the 
primers, nucleotides, the polymerase and the dye SYBR Green. During elongation dye molecules bind 
to the newly synthesized DNA. Fluorescence measurement at the end of the elongation step of every 
PCR cycle is performed to monitor the increasing amount of amplified DNA. 
 
Reactions are characterized by the point in time when the target amplification is first 
detected. This value is usually referred to as cycle threshold (Ct), the time at which 
fluorescence intensity is greater than background fluorescence. Consequently, the 
greater the quantity of target DNA in starting material, the faster a significant increase 
in fluorescent signal will appear, yielding a lower Ct (Marisa et al., 2005).  
 
3.2.10.2. Kinetic of the RT-PCR 
A reaction profile can be thought of has having three segments: an early background 
phase, an exponential growth phase (or log phase) and a plateau.  The background 
phase lasts until the fluorescence signal from the PCR product is greater than the 
background fluorescence of the probe system. The exponential growth phase begins 
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when sufficient product has accumulated to be detected above background. During 
this phase PCR reaches its optimal amplification period with the PCR product 
doubling after every cycle in ideal reaction conditions. The exponential phase ends 
when the reaction efficiency falls and the reaction enters the plateau. The plateau 
stage is reached when reaction components become limited and the fluorescence 
intensity is no longer useful for data calculation.  
 
 
 
Fig.3.7: Typical real-time PCR curves monitored on the LightCycler system. Fluorescence is blotted 
against cycle numbers. The curves can be divided into 3 segments: an early background phase, an 
exponential growth phase (log phase) and a plateau.  
 
3.2.10.3. Melting curve analysis 
 
Every DNA fragment melts at a characteristic temperature, called the melting 
temperature (Tm), defined as the temperature where 50% of the DNA is single 
stranded. The most important criteria that determine the Tm are the G+C content and 
the length of the fragment. The LightCycler Instrument is able to monitor the 
fluorescence continuously, while raising the temperature gradually. When the 
temperature in the capillary reaches the Tm of the fragment under study, this results 
in a sharp decrease in fluorescence. 
Each dsDNA product has its own specific Tm and checking the Tm of a PCR fragment 
can be compared with analyzing a PCR product by length in a gel electrophoresis. 
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GC content as well as length of a given PCR product influences the Tm. Smaller 
products like primer-dimers have lower Tm than specific fragments. 
 
      
 
Fig.3.8a: Melting curve analysis showing an abrupt fluorescence decline at 86°C in all of the samples 
indicating that only one specific product was amplified. 
Fig.3.8b: If the change in fluorescence –d(F1)/dT is plotted against Temperature in every sample a 
single melting peak at 86°C is monitored. 
 
3.2.10.4. Amplification efficiency 
 
In a PCR reaction in principle the amount of a target DNA-template is doubled with 
every cycle, so ideally the reaction can be described by the exponential function:  
                                                              
nyy 20=  
where y  is the quantity of target sequence at cycle n  and 0y  is the initial quantity of 
template.  
But due to the fact that in a realistic PCR not every template is replicated during 
every cycle, a PCR is better described by the equation: 
nEyy 0=   
where E  is the so called efficiency of the reaction. The maximum efficiency possible 
in PCR is two – every PCR product is replicated during every cycle. The minimum 
value is 1, corresponding to no amplification. 
slopeE /110−=  
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1. Absolute quantification: 
 
 
 
Fig.3.9: The resulting cycle numbers N of a dilution series are plotted against the initial log 
concentration. The received plot is linear and fits a trendline. Using the slope of this straight line the 
efficiency E of the PCR reaction can easily be calculated. 
 
3.2.10.5. Types of real-time quantification  
 
Target nucleic acids can be quantified using either absolute quantification or relative 
quantification. Absolute quantification determines the absolute amount of target 
(expressed in copy number or concentration), whereas relative quantification 
determines the ratio between the amount of target and  reference molecule, usually a 
suitable housekeeping gene.  
 
Relative (comparative) quantification 
 
The target concentration is expressed relative to the concentration of a reference 
gene (housekeeping gene) from the same sample material omitting the need for a 
standard with known concentrations.  The method is recommended for determining 
mRNA expression levels or gene doses values from tissue or cell cultures. 
 
Houskeeping genes 
 
The housekeeping genes are a large group of genes that code for proteins whose 
activities are essential for the maintenance of cell function. Detection of 
housekeeping gene mRNA has routinely been used to control several variables that 
may affect RT-PCR, for example, loss of degradation of RNA in the extraction 
protocol, differences in the amount of total RNA added to the reactions or variations 
in the efficiency of the reverse transcription or amplification steps. The most common 
housekeeping genes used are GAPDH, ß-actin, 18S and 28S rRNA, HPRT, ALAS, 
PBGD etc. 
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Gen Genomic structure/Pseudogenes Regulation 
ß-actin multigen family, 20 pseudogenes ↑: by thyroid gland hormones 
    ↑: stomach cancer 
γ-actin multigen family, pseudogenes   
GAPDH multigen family, many pseudogenes↑: lung-, pancreas-, intestinue- cancer
    ↑: insuline, EGF 
18S, 28S rRNA pseudogenes   
ß2-microglobulin no known pseudognes ↑: non-Hodking Lymphom, Tumors 
G6PDH no known pseudognes ↑: kidney-, stomach- cancer 
    ↑: hormones 
    ↑: growing factors 
PBGD no known pseudognes   
ALAS no known pseudognes   
HPRT pseudogenes   
Aldolase pseudogenes   
 
Tab.3.1: Housekeeping genes-regulation and pseudogenes  
(http://www.roche-applied-science.com/pack-insert/3310159a.pdf).  
 
To select a housekeeping gene optimal for normalization of a particular target 
transcript several aspect have to be considered. It is generally assumed that 
housekeeping genes which are essential for cell viability are constitutively expressed 
and the mRNA levels are similar in different cells types. However, the expression 
level of housekeeping genes varies depending on the cell type analysed and the 
expression of many housekeeping genes is regulated in a variety of cell types. 
Another point to be considered when choosing a reference gene as normalization 
standard for RT-PCR is that DNA may be amplified, even when the primers are 
carefully designed to bind to exon/intron boundaries to avoid amplification of 
contaminating tracer of DNA. Copy number of the individual housekeeping gene 
chosen for relative quantification should be in a similar range than that of the target 
gene to make comparative quantification possible. 
 
Porphobilinogen deaminase 
 
As a suitable housekeeping gene was chosen Porphobilinogen deaminase (PBGD). 
PBGD is a key enzyme of the heme synthesis pathway and catalyses successive 
condensations of four porphobilinogen molecules, in each case initiated by 
elimination of the amino group, to hydroxymethylbilane, a precursor of the porphyrin 
ring. The PBGD housekeeping gene is expressed in a broad range of tissues at a 
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relatively stable expression level and without known pseudogenes thus far. PBGD 
housekeeping gene belongs to the low abundance class of mRNAs. 
 
Standard curve for relative quantification 
 
The standard curve produces a linear relationship between Ct and initial amounts of 
cDNA. All samples and standards should have approximately equal amplification 
efficiencies.  
The PCR standard is a fragment of double-stranded DNA, single-stranded DNA  or 
cRNA bearing the target sequence. DNA standards can be synthesized by cloning 
the target sequence into a plasmid, purifying a conventional PCR product, or directly 
synthesizing the target nucleic acid (Marisa et al., 2005). 
Standard curves for adenosine receptors mRNAs, NO synthase mRNAs, kinin 
receptors mRNAs and PBGD mRNA were produced by using cDNA of all control BN 
rats, which was diluted 1:10, 1:100, 1:1000. 
 
3.2.10.6. Assay performance 
 
Real-time PCR was performed using LightCycler rapid thermal cycler according to 
the manufacturer´s instructions. Reactions were performed in a 10 µl volume with 
0.5µM primers and MgCl2 ranging from 3-5mM, Taq DNA polymerase, and buffer. 
MgCl2 concentrations were optimised and various annealing temperatures were 
tested to reach a good reaction efficiency. Optimised conditions were transferred to 
the following protocol. 
 
Reagent µl 
H2O 4.8 
MgCl2 (25mM) 1.2 
Forward primer (5µM) 1 
Reverse primer (5mM) 1 
SYBR Green  2 
 
Tab.3.2: Reaction mixture for real-time PCR 
 
A master mix was prepared from all reagents except of the cDNA template according 
to the Tab.3.2. A volume of 9µl of master mix was filled in the glass capillaries and 
1µl of cDNA was added. A negative control (without cDNA) was included in each run. 
Capillaries were closed, centrifuged and placed into a carousel in Light Cycler.  
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A four-step run experimental protocol was used as described in Tab.3.3. A single 
fluorescent measurement was performed at the end of each elongation phase. 
Specificity of the PCR products was documented with melting curve by continuous 
fluorescent measurement.   
 
Analysis Mode  Cycles Segment Target Temperature Hold Time Acquisition Mode
      Pre-Incubation     
None 1   95oC 10min none 
      Amplification     
Quantification 45 Denaturation 95oC 10s none 
  Annealing primer dependent 0-10s none 
  Extension 72oC  = (amplicon single 
    (bp) / 25) s  
      Melting Curve     
Melting Curves 1 Denaturation 95oC 0s none 
  Annealing 65oC 15s none 
  Melting 95oC/ slope =0.1oC/s 0s continuous 
      Cooling     
None 1   40oC 30s none 
 
Tab.3.3: protocol for LightCycler analysis 
  
3.2.10.7. RT-PCT Experiment Data Anaylsis 
 
The basic principle used in the analysis of real-time PCR data is that the number of 
cycles (Ct) necessary to reach a fixed concentration of amplicon in the reaction is an 
accurate estimator of the initial target concentration at the beginning of the reaction. 
The Ct values are generated from the Light Cycler software (Roche). 
 
Relative expression software tool (REST) 
 
Relative expression software tool (REST) was used for the gene expression analysis. 
REST allows a comparison of 15 target genes with a reference gene in two 
experimental groups up to 16 data points per group. Relative quantification of a 
target transcript is based on the mean Ct deviation of control and sample group, 
normalised by a reference transcript. Real-time PCR efficiency is included in the 
calculation.   
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This formula calculates the software factor of gene expression regulation. Another 
calculated value is the absolute gene regulation. A value of one indicates no change 
in target gene expression between the sample and calibrator sample. Values greater 
than one indicate up-regulation and values lower than one indicate down-regulation. 
REST uses the Pairwise Fixed Reallocation randomisation test to calculate result 
significance between samples and controls. This test is taking into account issues of 
reaction efficiency and reference gene normalisation.  
 
3.2.11. DETERMINATION OF NOX IN URINE AND PLASMA 
 
The half-life of nitric oxide in biological matrix is very short ranging from less than 1 s 
to ~30s. Nitric oxide production can be estimated from determining the 
concentrations of nitrite and nitrate products. The measurement of nitrite/nitrate 
concentration or of total nitrate and nitrite concentration (NOx) is routinely used as an 
index of NO production  (Moshage et al., 2005). 
 
Nitric oxide assay, fluoremietric 
  
The Nitric oxide Assay Kit, fluorimetric was used to  measure of total nitrit (NO2-) and 
nitrate (NO2-) concentration. The first step involves the conversion of nitrate to nitrite 
by the enzymatic action of nitrate reductase. The second step involves the addition of 
2,3-diaminonaphatalene (DAN) followed by NaOH to convert nitrite to a fluorescent 
compound 1(H)-naphthotriazole. Measurement of fluorescence of 1(H)-
naphthotriazole provides an accurate assay of (NO2-). 
 
 
Fig.3.10: Principle of measurement of nitrate and nitrite using 1(H)-naphthotriazole. 
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Assay performance 
 
Citrate plasma, stored at –20oC, was thawed on ice. The plasma samples were 
ultrafiltered through a 10kDa cut-off filter (Microcon YM-10, Milipore) for 30 min at 
12000 rpm. This procedure removes haemoglobin thereby avoiding the reduction in 
fluorescence intensity.   
Urine samples, stored at –20oC were thawed on ice. All urine samples were diluted 
1:100 with HPLC water.  
The nitrate standard curve was used for determination of total nitrate plus nitrite 
concentration in urine and plasma samples. For standard curve, nitrate and nitrite 
standards in concentrations 0.078; 0.156; 0.313; 0.625; 1.25; 2.5; 5 and 10µM were 
used. Each point of the standard curve was measured in duplicates.  
 
50µl of each standard concentration were added to 50µl of the assay buffer. 
10µl of ultrafiltered plasma were added to 70µl of assay buffer.   
10µl of 1:100 diluted urine samples were added to 70µl of assay buffer.  
 
To each sample and standard 10µl of the enzyme co-factors and 10µl of the nitrate 
reductase were added. All probes were incubated for 2 h at room temperature. After 
the incubation period 10µl of DAN reagent were added to each sample and incubated 
for 10 min. Then 20µl of NaOH were added to all samples. All samples were 
additionally diluted to total volume of 1ml with HPLC water. The fluorescence was 
measured in a fluorometer using the excitation wavelength of 375 nm and emission 
wavelength of 415 nm.  
Nitrate levels in plasma were expressed as µmol/l. Nitrate levels in urine were 
expressed as total nitrate and nitrite in µmol/100g of body weight per 24 h. The data 
was expressed as mean±SEM for 7 rats. An unpaired Student´s t-test was used for 
analysing the data. Probability value (P)<0,05 was considered to be significantly 
different. 
 
3.2.12. Cell culture 
 
Flp-In TREx-HEK293-Cells stably transfected with rat B1R or B2R, mouse B1R or B2R 
and human B1R or B2R were obtained from Prof. A. Faussner, Munich.  The cells 
were cultivated at 37oC in Dulbeco´s modified Eagle´s medium (DMEM), containing 
10% (v/v) fetal bovine serum, 2mM glutamine, supplemented with 50 units/ml 
penicillin and 50mg/ml streptomycin.  
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CELL HARVESTING  
Using a sterile pipette the culture medium was removed and discarded. 
Subsequently the cells were washed with 10ml calcium- and magnesium-free 
phosphate buffer saline (PBS) to remove all traces of foetal bovine serum (FBS). 
Trypsin solution (1ml) was added to the dish and incubated for 1 min. Further 5ml of 
growth medium was added to the cell suspension. The suspended cells were 
collected in a 15ml centrifuge tube and spinned at 900rpm for 4 min to obtain a cell 
pellet. The supernatant was removed from the centrifuged cells and the pellet was 
resuspended in a fresh DMEM medium. The amount of cells was counted and the 
appropriate dilutions were calculated. The correct amount of the cells was added to 
the culture vessel.  
 
CRYOGENIC PRESERVATION  
Cryogenic preservation (storage below –100oC) of cell cultures is widely used to 
maintain backups or reserves of cells without the associated effort and expense of 
feeding and caring for them. 
The confluent cells in 10cm dish were rinsed with 10ml PBS to remove all traces of 
FBS. Trypsin solution (1ml) was added to the dish and incubated for 1 min. Further 
5ml of growth medium was added to the cell suspension. The suspended cells were 
collected in a 15ml centrifuge tube and spinned at 900rpm for 4 min to obtain a cell 
pellet. The supernatant was removed from the centrifuged cells and the pellet was 
resuspended in enough of the cryoprotective medium containing 10% DMSO, 90% of 
DMEM with FCS to give a final cell concentration of 1 to 2x106 cells/ml. The cells 
suspension was then added to cryogenic vials. The vials were frozen in a polystyrene 
box in -80oC and after two days transferred to a liquid nitrogen freezer for permanent 
storage.  
 
CELL THAWING AND RECOVERY  
The vial with appropriate cells was placed in 37oC warm water, until completely 
thawed. The content of the vial was transferred in a dish containing culture medium. 
As soon as a majority of the cells have attached ( after 3 to 4 hours of incubation), 
the medium containing the diluted cryoprotective agent was removed and replaced 
with a fresh medium.   
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3.2.13. Measurement of [Ca2+]i 
 
In many cells, stimulation of cell-surface receptors that linked with the 
phosphoinositide pathway evokes a biphasic increase in intracellular free calcium 
concentration: an initial transient phase reflecting calcium release from internal stores 
is followed by a sustained phase due to calcium influx through calcium-selective 
channels in the plasma membrane. 
Changes in intracelullar calcium levels can be analyzed by using ion-sensitive 
indicators, whose light emission reflects the local concentration of the ion. 
Fluorescent Ca2+ indicators bind tightly to Ca2+ and are  excited at slightly longer 
wavelengths when they are free of Ca2+ than when they are in a Ca2+–bound form. By 
measuring the ratio of fluorescence intensity at two excitation wavelengths, the 
concentration ration of the Ca2+–bound indicator vs. the Ca2+–free indicator can be 
determined (http://herkules.oulu.fi/isbn9514268040/html/i1001924.html).  
 
 
 
Fig.3.11: Fluorescence emission of Fura-2. 
 
Assay performance 
 
For the measurement of [Ca2+]i cells were seeded on 12-mm-diameter polyornitin- 
coated glass covers (Sigma, at a concentration of 10 µg/ml) to enhance their 
adherence. Prior to experiment, cells were incubated with 5µg/ml Tetracycline for 24 
h to induce the receptor expression. 
For the measurement of [Ca2+]i  the appropriate cells were loaded with the 
acetoxymethylester (AM) form of 3 µM Fura-2/AM (Molecular Probes, Invitrogen) for 
45 min at 37°C. The nonadherent cells were removed by washing with Hank´s 
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balanced salt solution containing 2.5mM Ca2+ and 5.5mM glucose. The cells were 
additionally incubated further 30 min period for de-esterification.   
All experiments were performed at room temperature (20-22oC). Cells were 
stimulated with BK, KAL, KLP, des-Arg9-BK, des-Arg10-KAL and des-Arg10 -KLP in 
different concentrations (pM-µM). Ratiometric calcium signals were recorded using a 
Zeiss Axiovert135 microscope. Cells were excited alternatively with light of 340- and 
380-nm wavelengths. Resultant fluorescent emissions at both wavelengths were 
collected by a SesnsiCam CCD camera (PCO AG) and sampled every 425 
miliseconds. Recordings were made from 30-50 cells. Data analysis was performed 
using  TILLvisION software version 4.00 (TILL Photonics). 
 
 
 
 
 
 
 
 
 
 
 
  
                                                                                        
 
 
 
 
 
    
Values on the x axis indicate agonist concentration and values on the y axis indicate 
the measured 340/380-nm fluorescence ratio as an indicator of the intracellular-free 
[Ca2+]i. The results were evaluated using GraphPadPrism 4 software. The software 
calculates EC50 (the molar concentration of an agonist, which produces 50% of the 
maximum possible response for that agonist) and maximal effect.  
 
a 
c 
b 
Fig.3.12a: Cells before stimulation. 
Fig.3.12b: Cells after stimulation. Fluorescence 
at 340nm increases upon stimulation.     
Fig.3.12c: Cells after stimulation. Fluorescence 
at 380nm decreases upon stimulation.              
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Fig.3.14. Effect of kinin on [Ca2+]i in Fura-2-loaded HEK293 cells.  
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4. RESULTS 
 
The experiments were carried out with control BN rats and kininogen-deficient BNK 
rats. The animals received standard or high salt diet in presence or absence of 
spironolactone for 10 days.  
In chapter 4.1. we demonstrate production of nitrite/nitrate in urine and plasma of 
BN/BNK rats under different experimental conditions. Chapter 4.2 describes gene 
expression analysis of NO synthases (iNOS, eNOS and nNOS), adenosine receptors 
(A1-, A2A-, A2B-, A3-AR) and  bradykinin receptors (B1R and B2R) in different organs. 
This chapter is separated into three parts showing data on gene analysis of the 
kidney, atria and ventricles under different experimental conditions. In chapter 4.3. 
effects of kinins on B1R/B2R calcium signalling are presented.  
 
4.1. NITRITE / NITRATE PRODUCTION IN URIN AND PLASMA OF BN/BNK RATS 
 
Nitric oxide (NO) is of tremendous importance for the physiological function of 
vasculature. Endothelium-derived NO is responsible for a functioning of the 
cardiovascular system, which in turn may significantly affect other organs, notably the 
kidneys. The activity of NO synthase and nitric oxide production can be estimated 
from the concentrations of nitrite and nitrate products. Therefore the measurement of 
total nitrite/nitrate (NOx) concentration is routinely used as an index of NO 
production. 
 
4.1.1. NITRITE / NITRATE PRODUCTION IN THE URIN OF BN/BNK RATS 
 
NO metabolites are mainly excreted in the urine. Determination of urinary total NOx 
should describe potential difference in NO production between BN and BNK rats and 
the effects of standard or high salt diet in presence or absence of spironolactone. 
NOx in urine was determined fluorometrically at 365 nm after an enzymatic reaction. 
Results are presented in µmol of NOx per 100g of body weight in 24 hours. 
In both strains we found that high salt diet increased the urinary NOx level (2.4 fold).  
The difference between standard and high salt diet was statistically significant 
(P<0.01 in BN rats and P<0.05 in BNK rats).  In both strains the urinary NOx level 
were also significantly increased following high salt diet in combination with 
spironolactone treatment. BN rats displayed a 2.8-fold higher and BNK rats a 2.4-fold 
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higher urinary NOx levels after high salt diet in combination with spironolactone 
compared to the control rats group fed with standard diet (Fig.4.1, 4.2). 
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Fig.4.1: Effect of spironolactone and high salt diet on the NOx levels in urine of BN rats. Values are 
expressed as the mean ± SE, n=7. **P<0.01 BN-HS vs. BN-SD, §P<0.05 BN-HS+SP vs. BN-SD, 
$P<0.05 BN-HS+SP vs. BN-SD+SP. 
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Fig.4.2: Effect of spironolactone and high salt diet on the NOx levels in urine of BNK rats. Values 
are expressed as the mean ± SE, n=7.  **P<0.01 BNK-SD+SP vs. BNK-SD, §P<0.05 BNK-HS vs. 
BNK-SD, $$P<0.05 BNK-HS+SP vs. BNK-SD, &P<0.05 BNK-HS+SP vs. BNK-SD. 
 
In BN rats the spironolactone treatment did not change the urinary NOx level 
significantly. In contrast to BN rats, in BNK rats spironolactone treatment significantly 
increased the urinary nitrate levels (1.4-fold). Under high salt diet no significant effect 
of spironolactone treatment on the NOx production was observed (Fig.4.1, 4.2). 
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COMPARISON OF URINE NOx LEVELS IN BN vs. BNK RATS 
 
In urine of BNK rats fed with standard diet as well as with high salt diet the NOx level 
were slightly lower than those of BN rats. In contrast, in rats treated with 
spironolactone the urinary NOx level was significantly higher in BNK rats (1.3-fold) 
than in BN rats. This effect could not be observed under high salt diet and 
spironolactone treatment. Here we measured in BNK rats lower urinary NOx levels 
than in BN rats. 
 
4.1.2. NITRITE / NITRATE PRODUCTION IN THE PLASMA OF BN/BNK RATS 
 
Plasma NOx level describe potential difference in NO production between BN and 
BNK rats and the effect of high salt diet and spironolactone treatment. Prior to the 
measurement the plasma was ultrafiltered to remove haemoglobin and other possibly 
interacting proteins. NOx level in plasma was determined fluorometrically at 365 nm 
after an enzymatic reaction. NOx levels in plasma were expressed as µmol/l.  
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Fig.4.3: Effect of administration and high salt diet on the NOx levels in plasma of BN rats. Values 
are expressed as the mean ± SE, n=6.  
 
As shown in the Fig. 4.3. and 4.4. high salt diet and spironolactone administration 
seem to have no significant effects of on the plasma NOx production in both strains. 
In contrast to urinary NOx, high salt diet slightly decreased the plasma NOx 
production in both strains even after spironolactone treatment. 
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Fig.4.4: Effect of spironolactone and high salt diet on the NOx levels in plasma of BNK rats. Values 
are expressed as the mean ± SE, n=6. 
 
COMPARISON OF PLASMA NOx LEVELS IN BN vs. BNK RATS 
 
In BNK rats the plasma NOx levels in all experimental groups were lower than in BN 
rats. This effect was significant under high salt diet and after spironolactone 
treatment. In BNK rats under high salt diet the NOx levels in plasma were 1.6-fold 
lower than in BN rats. In plasma of BNK rats after spironolactone treatment the 
values of NOx were 1.4-fold lower than in BN rats. Under standard diet the BNK rats 
displayed also lower  plasma NOx levels, but the difference was statistically not 
significant (P=0.09). High salt diet in combination with spironolactone treatment did 
not yield any difference between the strains. 
 
SUMMARY OF NITRITE / NITRATE PRODUCTION IN THE URINE AND IN THE 
PLASMA OF BN/BNK RATS 
 
Following high salt diet, NOx levels significantly increased in urine of both strains but 
remained unchanged in plasma. High salt diet in combination with spironolactone 
treatment also increased the NOx levels in urine of both strains, however did not 
affect the plasma NOx levels in both strains. Spironolactone treatment did not effect 
the urinary NOx levels in BN rats and the plasma NOx levels in BN as well as BNK 
rats. Nevertheless, in BNK rats spironolactone treatment significantly increased the 
NOx level. When comparing BN and BNK rats we can say that in general the NOx 
levels were lower in kininogen-deficient BNK rats in urine as well as in plasma of 
almost all experimental groups. The difference between the strains was significant in 
plasma samples in the experimental group fed with high salt and in the experimental 
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group fed with standard diet in combination with spironolactone treatment. Higher 
NOx levels in BNK rats than in BN rats were measured only in urine after 
spironolactone treatment in combination with standard diet.  
 
4.2. GENE EXPRESSION ANALYSIS  
 
The mRNA-expression of adenosine-A1-, A2A-, A2B- and A3-AR, bradykinin B1R and 
B2R as well as of iNOS, eNOS and nNOS was examined in the kidney, the atria and 
the ventricles of BN and BNK rats using Real-Time PCR. The effects of high salt diet 
and standard diet in presence or absence of spironolactone were determined in both 
strains. The graphs display the relative gene expression ratios of the target gene, 
which is normalised to non-regulated housekeeping gene (PBGD). The basal relative 
expression of the gene is represented by the group fed with standard diet with the 
value of 1 (100%). Values lower than 1 indicate down-regulation and values greater 
than 1 indicate up-regulation of the gene of interest.  
 
4.2.1. Housekeeping gene 
 
For the relative quantification of target genes it was necessary to find a suitable 
housekeeping gene that is useful as standard gene. We tested rat porphobilinogen 
deaminase (PBGD), and 18S rRNA. We generated standard curves for these genes 
and examined the expression levels of PBGD and 18S rRNA in samples from the rat 
kidney.  
 
 
 
Fig.4.5: Standard curve of 18S rRNA-mRNA. The Kidney sample has Ct value of 15.19. 
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As shown by Fig.4.5. mRNA of 18S rRNA is abundantly expressed in the rat kidney. 
The Ct values of the kidney samples were approximately 15. 
 
 
 
Fig.4.6: Standard curve of PBGD-mRNA. The kidney samples have Ct values of approximately 25. 
 
In contrast, the PBGD gene, a low-abundance class housekeeping gene, was 
expressed moderately-Ct values of the kidney samples reached approximately 25 
(Fig.4.6). The genes of interest belong mainly to low-abundance genes. From this 
point of view, the PBGD gene, but not 18S rRNA gene, is a suitable control gene for 
our sample material. The level of expression of the target genes (A1-, A2A-, A2B-, A3-
AR;  iNOS, eNOS and nNOS; B1R and B2R) and of the PBGD housekeeping gene 
was in a similar range  to make comparative quantification possible. 
Furthermore, the expression level of the PBGD gene was examined in all samples. 
We had to determinate if the salt diet and spironolactone treatment influence the 
expression level of PBGD gene. In PBGD expression between the groups and strains 
in the kidney, ventricles and atria no significant differences were found, which makes 
the PBGD gene to be considered as a suitable housekeeping gene. 
  
Group Mean of Ct Standard Error
BN-SD 25.53 0.43 
BN-HS 25.63 0.41 
BN-SD+SPIRON. 25.25 0.19 
BN-HS+SPIRON. 25.72 0.34 
BNK-SD 25.24 0.13 
BNK-HS 25.60 0.15 
BNK-SD+SPIRON. 25.55 0.27 
BNK-HS+SPIRON. 25.64 0.27 
 
Tab.4.1: Ct values of PBGD housekeeping genes in the kidney of the experimental groups. 
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GENE EXPRESSION ANALYSIS OF THE KIDNEY 
 
4.2.2. NO synthase in the kidney of BN/BNK rats 
 
The free radical nitric oxide (NO) has been shown to play an important role in various 
physiological processes in the kidney, including salt and fluid reabsorption, renal 
hemodynamics, renin secretion and tubuloglomerular feedback mechanisms. All 
three NOS isoforms are differentially expressed throughout the kidney.  
The effects of treatment (standard diet ± spironoloactone, high salt diet ± spirono-
lactone) on the expression of eNOS-, iNOS- and nNOS-mRNA in the kidney of each 
strain should be determined. 
 
4.2.2.1. Neuronal NO synthase in the kidney of BN/BNK rats 
 
Neuronal NOS is a very low-abundance gene in the kidney. The highest expression 
was found in macula densa cells, where it regulates renin secretion. It is also 
expressed in principal cells in collecting duct. The function of nNOS in principal cells 
is still not clear. 
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Fig.4.7: Effect of spironolactone and high salt diet on the expression of nNOS-mRNA in kidney of BN 
rats. Values are expressed as the mean ± SE in reference to standard diet, n=10. *P<0.05 SD+SP vs. 
SD. 
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Fig.4.8: Effect of spironolactone and high salt diet on the expression of nNOS-mRNA in kidney of 
BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=10. *P<0.05 
SD+SP vs. SD, §§P<0.01 HS+SP vs. SD, $$P<0.01 HS+SP vs. HS. 
 
As depicted in the Fig.4.7 and 4.8, in both strains spironolactone administration 
demonstrated a significant down-regulation of nNOS-mRNA, 2.1-fold in BN rats and 
3.1-fold in BNK rats. In BNK rats this effect was obvious also under regulation of high 
salt diet in BNK rats. The level of nNOS-mRNA in BNK rats fed with high salt diet in 
combination with spironolactone was 3.3-fold lower than in BNK rats fed with high 
salt diet. BN rats in the same groups displayed a 1.7-fold down-regulation of nNOS, 
however the change did not reach statistical significance. 
Spironolactone administration in combination with high salt diet in comparison to 
standard diet alone caused a significant down-regulation of nNOS-mRNA in BNK rats 
(6.2-fold) and 1.6-fold down-regulation in BN rats.  
As shown in the Fig.4.7 and 4.8, high salt diet vs. standard diet displayed no 
significant effect. In BN rats high salt diet caused a moderate 1.4-fold upregulation of 
nNOS-mRNA expression and in BNK rats 1.5-fold down-regulation. 
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COMPARISON OF THE nNOS EXPRESSION IN THE KIDNEY OF BN AND BNK 
RATS 
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Fig.4.9: Differences between BN and BNK rats in nNOS-mRNA expression under standard and 
high salt diet in presence or absence of spironolactone in kidney. Values are expressed as the mean 
± SE in reference to standard diet, n=10. *P<0.05 HD+SP-BNK. vs. HD+SP-BN. 
 
Fig.4.9. shows that BNK rats fed with high salt diet in combination with 
spironolactone treatment displayed significantly (3-fold) lower nNOS-mRNA 
expression than the BN rats. In other experimental groups no significant differences 
of nNOS-mRNA expression were found between the strains.  
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4.2.2.2. Endothelial NO synthase in the kidney of BN/BNK rats 
 
Endothelial NOS is abundantly expressed in the renal microvasculature, in the 
glomerular endothelial cells, in the proximal tubular cells, in the thick ascending 
Henle´s loop and in the collecting tubule. Endothelial NO synthase belong to the 
intermediate-abundance gene in the rat kidney.  
 
SD SD+SP HS HS+SP
0.0
0.5
1.0
1.5
2.0
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
ra
tio
 (e
N
O
S/
PB
G
D
)
 
 
 
Fig.4.10: Effect of spironolactone and high salt diet on the expression of eNOS-mRNA in kidney of 
BN rats. Values are expressed as the mean ± SE in reference to standard diet, n=10. 
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Fig.4.11: Effect of spironolactone and high salt diet on the expression of eNOS-mRNA in kidney of 
BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=10. 
 
The expression of genes coding for eNOS did not show any significant difference 
between the strains and between the experimental groups. 
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4.2.2.3. Inducible NO synthase in the kidney of BN/BNK rats 
 
Inducible NOS is expressed in the proximal tubule. The gene for iNOS is a very low-
abundance gene in the rat kidney. 
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Fig.4.12: Effect of spironolactone and high salt diet on the expression of iNOS-mRNA in kidney of 
BN rats. Values are expressed as the mean ± SE in reference to standard diet, n=10. 
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Fig.4.13: Effect of spironolactone and high salt diet on the expression of iNOS-mRNA in kidney of 
BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=10. 
 
As depicted on the Fig.4.12 in BN rats the iNOS-mRNA expression moderately 
increased following high salt diet as well as after spironolactone treatment. In 
contrast, in BNK rats following high salt diet the iNOS-mRNA expression was 
lowered also in the combination with spironolactone treatment. Nevertheless, the 
differences in the expression did not reach the statistical significance. 
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COMPARISON OF THE iNOS EXPRESSION IN THE KIDNEY OF BN AND BNK 
RATS 
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Fig.4.14: Differences between BN and BNK rats in iNOS-mRNA expression under standard and 
high salt diet in presence or absence of spironolactone in kidney. Values are expressed as the mean 
± SE in reference to standard diet, n=10. *P<0.05 BNK-HS vs. BN-HS. 
 
In the kidney of BNK rats in comparison to BN rats fed with high salt we observed a  
significantly lower expression of nNOS-mRNA (2.8-fold). In BNK rats evoked high 
salt diet in combination with spironolactone decrease in nNOS-mRNA expression 
(2.5- fold). In other experimental groups no significant differences in the nNOS-
mRNA expression between the strains were found. 
 
SUMMARY OF NO SYNTHASES EXPRESSION IN THE KIDNEY OF BN AND BNK 
RATS 
 
High salt diet resulted in moderate increase in the expression of nNOS, iNOS and 
eNOS-mRNA in BN rats. In BNK rats opposite effect of the high salt diet could be 
observed in the expression of iNOS and nNOS. However, the differences evoked by 
high salt diet were not statistically significant. Spironolactone treatment significantly 
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down-regulated the expression of nNOS in both strains. In BNK rats, but not in BN 
rats, we measured significant down-regulation of the nNOS expression following high 
salt diet in combination with spironolactone treatment. In both strains following 
spironolactone treatment expression of iNOS slightly increased. In contrast, in BNK 
rats following spironolactone treatment in combination with high salt diet decreased 
the iNOS expression decreased. Additionally, spironolactone seems to have no effect 
on the eNOS expression in both strains. 
The expression of all three NOS isoforms was similar under standard diet. Also 
spironolactone treatment did not affect markedly the levels of NOS mRNA. 
Nevertheless, BNK rats following high salt diet also in combination with 
spironolactone displayed a decrease in the expression of nNOS and iNOS mRNA.   
 
4.2.3. ADENOSINE RECEPTORS IN THE KIDNEY 
 
The actions of adenosine are mediated through four receptors subtypes (A1-, A2A-, 
A2B- and A3-AR). All four subtypes of the adenosine receptor are present in the rat 
kidney. In most blood vessels, adenosine elicits marked vasodilatation, and this 
effect is mediated by A2A- and A2B-AR. In contrast, in the renal vasculature, 
adenosine can produce vasoconstriction through the activation of high-affinity A1AR. 
The exact effect of A3AR in the kidney remains still unclear. 
We wanted to determine if there is a connection between high salt diet and the 
expression of  ARs in the kidney. Further we wanted to examine the effects of 
spironolactone on the expression of ARs in the kidney. We compared the expression 
levels of BN and BNK rats in order to elicit if the kininogen deficiency affects the ARs 
expression in the kidney. 
 
4.2.3.1. A1AR adenosine receptor in the kidney of BN/BNK rats 
 
A1AR is a intermediate-abundance gene whose expression was documented in 
preglomerular vessels, in the juxtaglomerular apparatus, in the medullary collecting 
duct, and in descending vasa recta of the outer medulla. 
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Fig.4.15: Effect of spironolactone and high salt diet on the expression of adenosine A1AR-mRNA in 
kidney of BN rats. Values are expressed as the mean ± SE in reference to standard diet, n=10. 
***P<0.001 SD+SP. vs. SD, §§P<0.01 HS+SP. vs. SD, $P<0.05 HS+SP. vs. HS. 
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Fig.4.16: Effect of spironolactone and high salt diet on the expression of adenosine A1AR-mRNA in 
kidney of BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=10. 
**P<0.01 SD+SP. vs. SD, §§P<0.01 HS+SP. vs. SD, $$$P<0.05 HS+SP. vs. HS. 
 
As shown in the Fig.4.15. and Fig.4.16. spironolactone significantly down-regulated 
the expression of A1AR-mRNA in both strains, (5.3-fold in BN rats and 4.2-fold in 
BNK rats). Spironolactone elicited the same effect (A1AR-mRNA down regulation) 
also after high salt diet. In both strains spironolactone treatment in combination with 
high salt diet significantly down-regulated the A1AR-mRNA in comparison to high salt 
diet alone (2.4-fold in BN rats and 2.9-fold in BNK rats). 
High salt diet vs. standard diet displayed no significant effect in both strains (1.6-fold 
down-regulation in BN rats and 1.4-fold down-regulation in BNK rats). No significant 
differences in the A1AR-mRNA expression in the kidney were found between BN and 
BNK rats. 
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4.2.3.2. A3AR adenosine receptor in the kidney of BN/BNK rats 
 
A3AR is the least abundant adenosine receptor in the kidney. The exact locations of 
the A3AR in the kidney remains unclear.   
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Fig.4.17: Effect of spironolactone and high salt diet on the expression of adenosine A3AR-mRNA in 
kidney of BN rats. Values are expressed as the mean ± SE in reference to standard diet, 
n=10.*P<0.05 SD+SP vs. SD. 
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Fig.4.18: Effect of spironolactone and high salt diet on the expression of adenosine A3AR-mRNA in 
kidney of BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=10. 
*P<0.05 SD+SP vs. SD, §P<0.05 HS+SP vs. SD, $P<0.05 HS+SP vs. HS. 
 
We could observe a similar effect in the regulation of A3AR-mRNA expression after 
spironolactone treatment as in the regulation of the A1AR receptor. In comparison to 
standard diet spironolactone administration caused a significant down-regulation of 
the A3AR-mRNA in both strains (2.9-fold in BN rats and 2.7-fold in BNK rats). This 
effect of spironolactone administration was significant also under high salt diet in 
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BNK rats. Spironolactone administration in combination with high salt diet, in 
comparison to high salt diet alone, caused also a significant down-regulation of 
A3AR-mRNA (4.3-fold in BNK rats). In BN rats fed with high salt diet we could also 
observe a down-regulation of A3AR-mRNA-2.7-fold after spironolactone 
administration. This effect, however, did not reach statistical significance. 
High salt diet did not significantly affecte the A3AR-mRNA expression. We could 
measure a moderate up-regulation in both strains (2.1-fold in BN rats and 1.3-fold in 
BNK rats).   
To further identify the effect of kininogen deficiency we compared the expression of 
A3AR-mRNA between the BN and BNK rats of all experimental groups. No difference 
of A3AR-mRNA expression was found between BN and BNK rats. However, the 
A3AR-mRNA expression was slightly lower in the kidney of BNK rats in all 
experimental groups. 
 
4.2.3.3. A2AAR adenosine receptor in the kidney of BN/BNK rats 
 
A2AAR is a low-abundance gene in the rat kidney that is expressed mainly in renal 
blood vessels.  
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Fig.4.19: Effect of spironolactone and high salt diet on the expression of adenosine A2AAR-mRNA in 
kidney of BN rats. Values are expressed as the mean ± SE in reference to standard diet, n=7. 
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Fig.4.20: Effect of spironolactone and high salt diet on the expression of adenosine A2AAR-mRNA in 
kidney of BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=7. 
 
As shown in the Fig. 4.19. and Fig.4.20., following high salt diet we have observed a 
moderate up-regulation of A2AAR-mRNA in both strains. However, the expression of 
A2AAR-mRNA did not display any statistically significant difference between the 
strains and between the experimental groups.  
 
4.2.3.4. A2BAR adenosine receptor in the kidney of BN/BNK rats 
 
A2BAR was found predominantly in cortical tubular structures. A2BAR is a low-
abundance gene in the kidney. 
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Fig.4.21: Effect of spironolactone and high salt diet on the expression of adenosine A2BAR-mRNA in 
kidney of BN rats. Values are expressed as the mean ± SE in reference to standard diet, n=7. 
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Fig.4.22: Effect of spironolactone and high salt diet on the expression of adenosine A2BAR-mRNA in 
kidney of BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=7. 
 
Following high salt diet the A2BAR-mRNA expression was moderately up-regulated. 
This effect was more pronounced in BNK rats. Spironolactone treatment caused also 
a moderate increase in the A2BAR-mRNA expression in the kidney of both strains. 
The changes in the expression did not reach statistical significance. Between the 
strains no difference in the A2BAR-mRNA expression was determined.   
 
SUMMARY OF ADENOSINE RECEPTORS EXPRESSION IN THE KIDNEY OF BN 
AND BNK RATS 
 
In both strains A1- and A3-AR seem to be similarly regulated by spironolactone 
treatment. The expression of both, A1- and A3-AR was significantly down-regulated 
after spironolactone treatment also in combination with high salt diet. High salt diet 
slightly decreases the A1AR expression in both strains, however the difference was 
not statistically significant. In contrast, following high salt diet A3AR expression was 
up-regulated in both strains. The statistical significance was not reached, probably 
due to relative great variance among single values. In the kidney samples of both 
strains high salt diet, as well as spironolactone administration seem to have no 
significant effect on the A2A-, A2B-AR expression. 
As we could not determine any marked difference between BNK rats and control BN 
rats, we can conclude, that the kininogen deficiency does not affect the expression of 
ARs in the kidney.  
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4.2.4. Bradykinin receptors in the kidney 
 
Bradykinin is one of the most important peptides in regulating vascular tone, water, 
and ionic balance in the body. The actions of bradykinin are mediated by two 
receptors subtypes B1R and B2R. B2R could be detected in tubular system as well as 
in the renal vasculature. B1R is very poorly expressed under normal physiological 
conditions. 
The effects of treatment (standard diet ± spironoloactone, high salt diet ± spirono-
lactone) on the expression of B1R and B2R in each strain should be determined. 
Furthermore, we were intersted in analysing the expression of B1R and B2R in 
kininogen-deficient BNK rats and in control BN rats.  
 
4.2.4.1. Bradykinin B2R in the kidney of BN/BNK rats 
 
B2R is a intermediate abundance gene in the kidney. B2R are present mainly on the 
epithelial cells of the medullary collecting duct, but also in the glomerulus, proximal 
straight tubules, cortical thick ascending limb of Henle´s loop, and distal convoluted 
tubule.  
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Fig.4.23: Effect of spironolactone and high salt diet on the expression of B2R-mRNA in kidney of BN 
rats. Values are expressed as the mean ± SE in reference to standard diet, n=7. 
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Fig.4.24: Effect of spironolactone and high salt diet on the expression of B2R-mRNA in kidney of 
BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=7. 
 
As depicted in the Fig.4.23 and 4.24 neither high salt diet, nor sprinolactone 
administration caused significant changes in the expression of B2R-mRNA in the 
kidney of BN and BNK rats. In BN rats, but not in BNK rats following high salt diet in 
combination with spironolactone treatment we measured slightly increased B2R-
mRNA expression. In all experimental groups the expression levels of B2R-mRNA 
were similar between the strains in all experimental groups.  
 
4.2.4.2. Bradykinin B1R in the kidney of BN/BNK rats 
 
Under physiological conditions is the expression of B1R-mRNA very low. Following 
induction B1R-mRNA expression could be determined in the efferent arteriole, the 
medullary thin limb and in the distal tubule.  
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Fig.4.25: Effect of spironolactone and high salt diet on the expression of B1R-mRNA in kidney of BN 
rats. Values are expressed as the mean ± SE in reference to standard diet, n=7. *P<0.05 HS vs. SD. 
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Fig.4.26: Effect of spironolactone and high salt diet on the expression of B1R-mRNA in kidney of 
BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=7.  
 
As reported before, in the rat kidney the B1R-mRNA expression was very low (Ct 
values ranged from 31-33). Fig. 4.25 and 4.26 show that in both strains high salt diet 
increased the B1R-mRNA expression. In BN rats the effect was more pronounced 
and also statistically significant in BN rats (2.3-fold). In BN rats high salt diet in 
combination with spironolactone slightly increased the expression of B1R-mRNA, 
whereas in BNK rats we could observe the opposite effect. Under standard diet the 
B1R-mRNA expression remained similar in both strains. BNK rats displayed 
moderate down-regulation of B1R-mRNA expression following high salt. 
 
SUMMARY OF BRADYKININ RECEPTORS EXPRESSION IN THE KIDNEY OF BN 
AND BNK RATS 
 
In the kidney of both strains neither high salt diet nor spironolactone administration 
significantly changed the expression of B2R-mRNA. In the kidney of BN rats but not 
BNK rats high salt diet significantly increases the expression of B1R-mRNA. In BNK 
rats following high salt diet with and without spironolactone treatment the B1R-mRNA 
expression was slightly lower than in BN rats, however the changes were not 
statistically significant.  
 
GENE EXPRESSION ANALYSIS OF THE ATRIA 
 
The expression of genes for iNOS, eNOS and nNOS, adenosine-A1-, A2A-, A2B- and 
A3-AR as well as bradykinin B1R and B2R mRNA were investigated in atria of BN and 
BNK rats. As the expression of all these genes remained unchanged in atria of both 
rat strains, the data have not been shown in detail. The results of the gene 
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expression analysis indicate, that neither high salt diet nor spironolactone 
administration influence the expression of iNOS, eNOS and nNOS, adenosine-A1-, 
A2A-, A2B- and A3-AR as well as bradykinin B1R and B2R mRNA in atria of BN and 
BNK rats.  
 
GENE EXPRESSION ANALYSIS OF THE VENTRICLES 
  
4.2.5. NO synthase in the ventricles 
 
The constitutive isoforms, nNOS and eNOS are both found in the normal heart in a 
restricted distribution: nNOS was detected primarily in nerves innervating the heart, 
eNOS in the endocardial and vascular endothelium as well as in cardiomyocytes. In 
contrast, iNOS may be expressed in all cell types in response to an adequate 
stimulus.  
 
4.2.5.1. Neuronal NO synthase in ventricles of BN/BNK rats 
 
Neuronal NOS is a very low-abundance gene in the ventricles expressed mainly in 
nerves. 
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Fig.4.27: Effect of spironolactone and high salt diet on the expression of nNOS-mRNA in ventricles 
of BN rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. 
 
In BN rats no significant effect of high salt diet and of spironolactone treatment was 
determined. High salt diet with and without spironolactone slightly lower the nNOS 
expression. Spironolactone treatment alone caused also a moderate down-regulation 
of nNOS-mRNA expression in BN rats. However, in BNK rats following 
spironolactone treatment as well as high salt diet the nNOS-mRNA expression in 
ventricles was significantly down-regulated (4.2-fold and 9.4-fold, respectively). 
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Fig.4.28: Effect of spironolactone and high salt diet on the expression of nNOS-mRNA in ventricles 
of BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. **P<0.01 
BNK-HS+SP vs. BNK-SD, §§§P<0.001 BNK-HS vs. BNK-SD, $$$P<0.001 BNK-HS+SP vs. BNK-HS,  
&&P<0.01 BNK-HS+SP vs. BNK-SD+SP. 
 
Further, in BNK rats high salt diet in combination with spironolactone treatment 
significantly increased the nNOS-mRNA expression (10-fold) in comparison to high 
salt diet alone.  
 
COMPARISON OF THE nNOS EXPRESSION IN VENTRICLES OF BN/BNK RATS 
 
SD
BN BNK
0
1
2
3
4
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
ra
tio
 (n
N
O
S/
PB
G
D
)
 
HS
BN BNK
0
1
2
3
4
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
ra
tio
 (n
N
O
S/
PB
G
D
)
 
SD+SP
BN BNK
0
1
2
3
4
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
ra
tio
 (n
N
O
S/
PB
G
D
)
 
HS+SP
BN BNK
0
2
4
6
8 **
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
ra
tio
 (n
N
O
S/
PB
G
D
)
 
 
Fig.4.29: Differences between BN and BNK rats in nNOS-mRNA expression under standard and 
high salt diet in presence or absence of spironolactone in ventricles. Values are expressed as the 
mean ± SE in reference to standard diet, n=6. **P<0.01 BNK-HS+SP vs. BN-HS+SP. 
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In BNK rats following high salt diet in combination with spironolactone we measured 
a 4.7 higher expression of nNOS-mRNA than in BN rats. In other experimental 
groups no significant differences between the strains were found. However, following 
high salt diet ventricles of BNK rats displayed 2.9-fold lower nNOS-mRNA 
expression. 
 
4.2.5.2. Endothelial NO synthase in ventricles of BN/BNK rats 
 
Endothelial NOS is intermediate-abundance gene in the ventricles, expressed mainly 
in endothelium and in cardiomyocytes. 
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Fig.4.30: Effect of spironolactone administration and high salt diet on the expression of eNOS-mRNA 
in ventricles of BN rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. 
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Fig.4.31: Effect of spironolactone and high salt diet on the expression of eNOS-mRNA in ventricles 
of BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. *P<0.05 
BNK-HS+SP vs. BNK-SD, §§§P<0.01 BNK-HS+SP vs. BNK-SD+SP. 
 
In BNK rats following high salt diet and spironoactone the eNOS-mRNA expression 
did not significantly change. While in BNK rats, spironolactone treatment slightly 
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increased the eNOS-mRNA expression. Following high salt diet we could observe a 
2.4-fold up-regulation of eNOS-mRNA. In BNK rats high salt in combination with 
spironolactone significantly upregulated the eNOS-mRNA expression (2.7-fold). 
 
COMPARISON OF THE eNOS EXPRESSION IN VENTRICLES OF BN/BNK RATS 
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Fig.4.32: Differences between BN and BNK rats in eNOS-mRNA expression under standard and 
high salt diet in presence or absence of spironolactone in ventricles. Values are expressed as the 
mean ± SE in reference to standard diet, n=6. *P<0.05 BNK-SD vs. BN-SD. 
 
Under standard salt diet BNK rats displayed significantly lower expression of eNOS-
mRNA in comparison to BN rats (3.2-fold). In other experimental groups no 
significant difference in the eNOS-mRNA expression between the two strains was 
found.  
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4.2.5.3. Inducible NO synthase in the ventricles of BN/BNK rats 
 
Inducible NOS is very low-abundance gene in the ventricles that can be highly up-
regulated in response to an adequate stimulus. 
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Fig.4.33: Effect of spironolactone and high salt diet on the expression of iNOS-mRNA in ventricles of 
BN rats. Values are expressed as the mean ± SE in reference to standard diet, n=6.  
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Fig.4.34: Effect of spironolactone and high salt diet on the expression of iNOS-mRNA in ventricles of 
BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. **P<0.01 BNK-
SD+SP vs. BN-SD, §§P<0.01 BNK-HS vs. BNK-SD, $$$P<0.001 BNK-HS+SP vs. BNK-SD. 
 
In BN rats high salt diet with and without spironolactone and spironolactone alone 
lowered the iNOS-mRNA expression. Nevertheless, the differences in iNOS-mRNA 
expression did not reach statistical significance. In contrast, in BNK rats 
spironolactone treatment significantly increased the iNOS-mRNA expression under 
both, the standard diet (12.4-fold) as well as high salt diet (16.16-fold). High salt diet 
also significantly up-regulated the iNOS-mRNA expression in ventricles of BNK rats 
(9.1-fold). 
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COMPARISON OF THE iNOS EXPRESSION IN VENTRICLES OF BN/BNK RATS 
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Fig.4.35: Differences between BN and BNK rats in iNOS-mRNA expression under standard and 
high salt diet in presence or absence of spironolactone in ventricles. Values are expressed as the 
mean ± SE in reference to standard diet, n=6. ***P<0.001 BNK- SD vs. BN-SD. 
 
The iNOS-mRNA expression was lower in BNK rats of all experimental groups. 
Under standard diet BNK rats displayed significantly lower expression of iNOS-
mRNA (21.4-fold) than BN rats. BNK rats fed with high salt diet demonstrated 2.1-
fold lower iNOS-mRNA expression in comparison to BN rats however the difference 
did not reach statistical significance.  
 
SUMMARY OF NO SYNTHASES EXPRESSION IN THE VENTRICLES OF BN/BNK 
RATS 
 
In ventricles of BN rats we did not find any significant difference in the expression of 
nNOS, eNOS and iNOS-mRNA between the experimental groups. BNK rats following 
high salt diet displayed a significantly lower expression of nNOS-mRNA. In contrast, 
in BNK rats high salt diet in combination with spironolactone caused a significant 
increase in the nNOS-mRNA expression (10-fold) in comparison to high salt diet 
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alone. In BNK rats following spironolactone treatment the nNOS-mRNA significantly 
decreased (4.2-fold). In contrast to nNOS, we could observe opposite trend in the 
regulation of eNOS and iNOS-mRNA expression after high salt diet and 
spironolactone administration.  Following high salt with and without spironolactone 
we could observe an increase in the expression of both, iNOS and eNOS. 
Spironolactone treatment also up-regulated the expression of iNOS and eNOS-
mRNA in ventricles of BNK rats (12.4- and 1.6-fold, respectively). 
The expression of all three NOS was predominantly lower in BNK rats. We could 
determine significantly lower expression of eNOS and iNOS-mRNA in BNK rats fed 
with standard in comparison to BN rats. On the other hand, in BNK rats following high 
salt diet in combination with spironolactone treatment the nNOS-mRNA expression 
was significantly higher in BNK rats than in BN rats. 
 
4.2.6. Adenosine receptors in the ventricles 
  
Adenosine is an endogenous compound that is generated in response to hypoxia 
and -adrenergic stimulation in the heart. Adenosine appears to directly protect 
cardiomyocytes or myocardial tissue against ischemia. Endogenous adenosine may 
protect via one or all of the four characterized AR subtypes-A1-,A2A-, A2B-, and A3-
ARs.  
We wanted to determine if there is a connection between high salt diet and the 
expression of  ARs in the ventricles. Further we wanted to examine the effects of 
spironolactone on the expression of ARs in the ventricles. We compared the 
expression levels of BN and BNK rats in order to elicit if the kininogen deficiency 
affects the ARs expression in the ventricles. 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
78 
4.2.6.1. A1AR adenosine receptor in the ventricles of BN/BNK rats 
 
A1AR is expressed in ventricular cardiomyocytes and it protects against the injury 
caused by myocardial ischemia. A1AR is a intermediate-abundance gene in rat 
ventricles. 
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Fig.4.36: Effect of spironolactone and high salt diet on the expression of adenosine A1AR-mRNA in 
ventricles of BN rats. Values are expressed as the mean ± SE in reference to standard diet, n=6.  
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Fig.4.37: Effect of spironolactone and high salt diet on the expression of adenosine A1AR-mRNA in 
ventricles of BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. 
 
No significant differences in the A1AR-mRNA expression between the experimental 
groups were determined. However, following spironolactone administration we could 
observe opposite tendencies in the regulation of A1AR-mRNA expression between 
BN and BNK rats. Whereas in BN rats after spironolactone administration the A1AR-
mRNA expression decreases, in BNK rats a moderate up-regulation of the A1AR-
mRNA expression was observed. 
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4.2.6.2. A3AR adenosine receptor in the ventricles of BN/BNK rats 
 
A3AR belongs to a very low-abundance gene in the ventricles. Adenosine mediates a 
cardioprotective effect via the A3AR. 
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Fig.4.38: Effect of spironolactone and high salt diet on the expression of adenosine A3AR-mRNA in 
ventricles of BN rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. 
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Fig.4.39: Effect of spironolactone and high salt diet on the expression of adenosine A3AR-mRNA in 
ventricles of BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. 
**P<0.01 BNK-SD+SP vs. BNK-SD, §§P<0.01 BNK-HS vs. BNK-SD, $$$P<0.001 BNK-HS+SP vs. BNK-
SD. 
 
In BN rats following high salt diet the expression of A3AR-mRNA increased 1.6-fold. 
In addition spironolactone caused a moderate down-regulation of A3AR-mRNA. 
However, the differences were not statistically significant. As shown in the Fig. 4.39 
in BNK rats following high salt diet with and without spironolactone administration we 
could observe a significant down-regulation of A3AR-mRNA (3.2-fold and 3.9-fold, 
respectively). In BNK rats spironolactone administration significantly decreased the 
A3AR-mRNA expression (4.3-fold).  
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No significant differences were found in the A3AR-mRNA expression between both 
strains.  
 
4.2.6.3. A2AAR adenosine receptor in the ventricles of BN/BNK rats 
 
A2AAR is a intermediate abundance gene in the ventricles of rat. The exact role of 
A2AAR in heart remain unclear, but there is a strong evidence, that this receptor is 
modulating adrenergic functions. 
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Fig.4.40: Effect of spironolactone and high salt diet on the expression of adenosine A2AAR-mRNA in 
ventricles of BN rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. 
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Fig.4.41: Effect of spironolactone and high salt diet on the expression of adenosine A2AAR-mRNA in 
ventricles of BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. 
 
In both strains following spironolactone administration under standard as well as high 
salt diet A2AAR expression slightly decreased. In BN rats high salt diet caused 
moderate down-regulation of A2AAR-mRNA. In contrast, in BNK rats high salt diet 
slightly up-regulated the A2AAR expression. However, the differences between the 
experimental groups and between strains did not reach statistical significance. 
RESULTS 
81 
4.2.6.4. A2BAR adenosine receptor in the ventricles of BN/BNK rats 
 
A2BAR is a low-abundance gene in the ventricles. The exact role of A2BAR in the 
heart tissue is still not entirely clear. Nevertheless, it is know that it mediates 
vasodilatation and increases mast cell release. 
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Fig.4.42: Effect of spironolactone and high salt diet on the expression of adenosine A2BAR-mRNA in 
ventricles of BN rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. 
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Fig.4.43: Effect of spironolactone and high salt diet on the expression of adenosine A2BAR-mRNA in 
ventricles of BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. 
 
As shown in the Fig.4.42 in BN rats high salt diet as well as spironolactone 
administration did not change the expression of A2BAR-mRNA. In BNK rats following 
high salt diet and spironolactone we observed a moderate down-regulation of A2BAR-
mRNA expression. Nevertheless, the expression of A2BAR-mRNA did not display any 
statistically significant differences between the experimental groups and between the 
two strains.  
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SUMMARY OF ADENOSINE RECEPTORS EXPRESSION IN THE VENTRICLES 
OF BN AND BNK RATS 
 
In ventricles of both strains neither high salt diet nor spironolactone administration 
changed significantly the expression of A1AR, A2AAR and A2BAR-mRNA. In BN rats 
spironolactone in combination with standard as well as high salt diet caused a 
moderate decrease in A1AR, A3AR, A2AAR-mRNA expression and did not affect the 
A2BAR-mRNA expression. In contrast to BN rats, in BNK rats spironolactone 
increased the A1AR-mRNA expression. In BNK rats spironolactone lowered 
significantly the expression of A3AR under standard as well as high salt diet.  
In BN rats high salt diet increased the A3AR-mRNA expression. In contrast, in BNK 
rats following high salt we could observe a significant down-regulation of A3AR-
mRNA expression.  
No significant differences were found in the expression of all four adenosine receptor 
between the strains. Nevertheless, in BNK rats of all experimental group the A1AR-
mRNA expression was lower than in BN rats.  
 
4.2.7. Bradykinin receptors in the ventricles 
 
In the cardiovascular system, the classical action of kinins is vasodilatation, 
modulation of cell growth and modulation of myocardial responses to ischemia. The 
action of kinins is mediated through two G-protein coupled receptors-B1R and B2R. 
Both receptors are present in the rat ventricles.  
The effects of treatment (standard diet ± spironoloactone, high salt diet ± spirono-
lactone) on the expression of B1R and B2R in each strain should be determined. 
 
4.2.7.1. Bradykinin B2R in the ventricles of BN/BNK rats 
 
B2R is expressed in endothelial as well as in smooth muscle cells of ventricles. B2R 
belongs to very low-abundance gene in the ventricles.  
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Fig.4.44: Effect of spironolactone and high salt diet on the expression of B2R-mRNA in ventricles of 
BN rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. 
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Fig.4.45: Effect of spironolactone and high salt diet on the expression of B2R-mRNA in ventricles of 
BNK rats. Values are expressed as the mean ± SE in reference to standard diet, n=6. *P<0.05 BNK-
HS vs. BNK-SD. 
 
In both strains spironolactone administration lowered the expression of B2R-mRNA 
(1.7-fold in BN and 1.8-fold in BNK rats). High salt diet with and without 
spironolactone also slightly down-regulated the B2R-mRNA expression in BN rats. 
BNK rats following high salt diet displayed a significant B2R-mRNA down-regulation 
(3.3-fold).  
BNK rats fed with high salt diet demonstrated a 2.1-fold lower B2R-mRNA expression 
in comparison to BN rats. However, the difference did not reach statistical 
significance. In other experimental groups the B2R-mRNA expression was similar in 
both strains.  
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4.2.7.2. Bradykinin B1R in the ventricles of BN/BNK rats 
 
B1R is expressed by the same cell types in ventricles as B2R, by endothelial and 
smooth muscle cells. B1R is very weakly-abundance gene in the ventricles. 
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Fig.4.46: Effect of spironolactone and high salt diet on the expression of B1R-mRNA in atria of BN 
rats. Values are expressed as the mean ± SE in reference to standard diet, n=6.  
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Fig.4.47: Effect of spironolactone and high salt diet on the expression of B1R-mRNA in atria of BNK 
rats. Values are expressed as the mean ± SE in reference to standard diet, n=6.  
 
As shown in the Fig.4.46 in BN rats following high salt diet a moderate 1.7-fold up-
regulation of B1R-mRNA was observed. In contrast, in BNK rats high salt diet slightly 
decreased the B1R-mRNA (1.6-fold). In both strains spironolactone treatment down-
regulated the B1R-mRNA expression (2.9-fold in BN and 2.2-fold in BNK rats). 
However the differences between the experimental groups did not reach statistical 
significance. 
The expression of B1R-mRNA in the ventricles of BNK rats was slightly lower in all 
experimental groups, nevertheless not significantly. The differences between the 
strains were more expressive following high salt diet than following standard diet.   
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SUMMARY OF BRADYKININ RECEPTOR EXPRESSION IN THE VENTRICLES 
OF BN/BNK RATS 
 
Following high salt diet the expression of B2R-mRNA decreased in both strains. 
However, the down-regulation was only statistically significant in BNK rats. High salt 
diet slightly lowered also the expression of B1R-mRNA in BNK rats. In contrast, BN 
rats under high salt diet demonstrated increased B1R-mRNA expression. 
Nevertheless, this change was not significant due to a relative great variance among 
the single values. Spironolactone treatment decreased the expression of both, B1R- 
and B2R-mRNA in both strains, also in the combination with high salt diet. 
No significant difference in the B2R mRNA expression was determined between BN 
and BNK rats. We could show that BNK rats express lower B1R-mRNA levels under 
all experimental conditions, but the differences between both strains were not 
statistically significant.  
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4.3. CALCIUM SIGNALLING OF B1R AND B2R 
 
It was believed that in rodent on B1R des-Arg9-BK is more potent agonist than des-
Arg10-KAL. Further, it was assumed that BK is the only kinin in this species as no 
KAL might be present in rat. Recently our group found a kallidin-like-peptide (KLP), a 
novel kinin agonist in the rat. On the basis of the data presented by Prof. F. Hess in 
the Kinin congress in Lund in 2006 (see Tab.4.2) we decided to prove the efficacy 
and potency of kinins, including the novel agonist KLP and its des-Arg-metabolite on 
cell lines expressing  B1R/B2R of different species. 
 
 Ki (nM)   
  rabbit rodent (mouse, rat) human 
des-Arg10-KAL 0.2 7.5 0.14 
des-Arg9-BK 30 0.7 120 
 
Tab.4.2: Dissociation constants (Ki) of kinins. Data presented from Prof. Hess, 2006. 
 
Flp-In TREx-HEK293-cells expressing B1R/B2R of human, rat and mouse were 
provided by Prof. Faussner´s laboratory.  Using these cell lines we examined the 
concentration-response relationship of kinin signalling by measuring intracellular 
calcium levels. The effects of BK, KAL, KLP, des-Arg9-BK, des-Arg10-KAL and des-
Arg10-KLP were investigated. Changes in intracellular calcium levels were analysed 
with the use of ion-sensitive indicator Fura-2.  
Kinins induced a immediate increase in intracellular calcium which peaked within 
∼10-20 s and diminished afterward. Stimulation of Flp-In TREx-HEK293-cells 
expressing the B1R/B2R with increasing kinin concentrations showed a dose 
dependent rise of the calcium signal. After a certain concentration a steady state was 
reached and the maximal response remained approximately equal. Fig.4.48 depicts 
the concentration-response relationship of kinin signalling on intracellular calcium 
levels.  
The apparent agonist affinities are expressed as EC 50 (the concentration of an 
agonist that produces 50% of the maximal possible effect of the agonist). Data are 
represented as means±SEM from multiple experiments. The maximal effect 
represents increase of the intracellular Ca2+ concentration (difference in the 340/380 
ratio). 
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Fig.4.48. Effect of des-Arg10-KAL on calcium signal in Fura-2-loaded HEK293 cells expressing human 
B1R.  The figure shows the time course of a response at a fluorescence ratio of 340/380. 
 
4.3.1. Calcium signalling of HEK293 cells 
 
Not transfected HEK293 cells were used as a negative control. Stimulation of 
HEK293 cells with 10µM des-Arg9-BK, des-Arg10-KAL and des-Arg10-KLP did not 
lead to increase of intracellular calcium-[Ca2+]i in the HEK293 cells. However, 
stimulation with BK, KAL and KLP caused a moderate calcium increase (see 
Fig.4.49). 
In HEK293 cells the minimal concentration for stimulation with BK, KAL and KLP was 
100 nm. The maximal response was reached at 10µM. The effective concentration 
(EC50) calculated from the concentration-response curves was 1.3µM for BK, 660nM 
for KAL and 1.7µM for KLP. The maximal effect was approximately equal in all three 
agonists and reached the value of 130 arbitrary units (a.U). 
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Fig.4.49: Concentration-response relationship of BK, KAL and KLP signalling in native HEK293 cells. 
 
Agonist EC50 (M) Max effect 
BK 1.3*10-6 139 
KAL 6.6*10-7 132 
KLP 1.7*10-6 128 
 
Tab.4.3: EC50 and maximal effect of kinin induced increase in [Ca2+]i in HEK293 cells. Data are 
means from at least three experiments.   
 
We can conclude that HEK293 cells do not express the B1R, because we could not 
measure any calcium signal after stimulation with des-Arg-metabolites. However, we 
could measure a moderate increase in [Ca2+]i after stimulation with BK, KAL and 
KLP. Nevertheless, after BK, KAL and KLP stimulation the maximal reached effect is 
was in the HEK293 cells very low. In HEK293 cells KAL is approximately 5-fold more 
potent agonist than BK and KLP. According to this results we assume a low 
expression of B2R in HEK293 cells.  
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4.3.2. Calcium signalling of cells expressing rat B1R 
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Fig.4.50: Concentration-response relationship of des-Arg9-BK, des-Arg10-KAL and des-Arg10-KLP 
signalling on rat B1R. 
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Fig.4.51: Concentration-response relationship of BK, KAL and KLP signalling on rat B1R. 
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Agonist EC50 (M) Max effect 
des-Arg9-BK 7.6*10-9 416 
des-Arg10-KAL 3.7*10-9 418 
des-Arg10-KLP 2.6*10-9 412 
BK 2.3*10-7 350 
KAL 2.7*10-7 355 
KLP 2.4*10-7 359 
 
Tab.4.4: EC50 and maximal effect of kinin induced increase in [Ca2+]i in cells expressing rat B1R. Data 
are means from at least three experiments.   
               
In cells expressing rat B1R the threshold concentration for stimulation  with des-Arg9-
BK, des-Arg10-KAL and des-Arg10-KLP was 0.01nM and the maximal response was 
observed at 1000nM. The effective concentration (EC50) calculated from the 
concentration-response curves was 7.6nM for des-Arg9-BK, 3.7nM for des-Arg10-KAL 
and 2.6nM for des-Arg10-KLP. The maximal effect reached the value of 415 a.U and 
was approximately equal in all three agonists. 
In cells expressing rat B1R the minimal concentration for stimulation with BK, KAL 
and KLP was 10nM. The maximal effect was reached at 10µM. The effective 
concentration (EC50) calculated from the concentration-response curves was 
23.2µm for BK, 26.6µM for KAL and 23.6µM for KLP. The maximal effect was 
approximately equal in all three agonists and achieved the value of 355 a.U. 
We can summarize that the des-metabolites displayed similar effects on rat B1R. The 
kinins (BK, KAL, KLP) were approximately 100-fold less potent and were also less 
efficacious on the rat B1R.  
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4.3.3. Calcium signalling of cells expressing rat B2R 
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Fig.4.52: Concentration-response relationship of BK, KAL and KLP signalling on rat B2R. 
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Fig.4.53: Concentration-response relationship of des-Arg9-BK, des-Arg10-KAL and des-Arg10-KLP 
signalling on rat B2R. 
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Agonist EC50 (M) Max effect 
BK 3.0*10-12 403 
KAL 4.3*10-12 437 
KLP 7.4*10-12 473 
des-Arg9-BK 4.2*10-8 482 
des-Arg10-KAL 6.4*10-8 458 
des-Arg10-KLP 4.0*10-8 465 
 
Tab.4.5: EC50 and maximal effect of kinin induced increase in [Ca2+]i in cells expressing rat B2R. Data 
are means from at least three experiments.   
               
In cells expressing rat B2R the threshold concentration for stimulation with BK, KAL 
and KLP was 0.1pM and the maximal response was observed at 10nM. The effective 
concentration (EC50) calculated from the concentration-response curves was 3.0pM 
for BK, 4.3pM for KAL and 7.4pM for KLP. The strongest maximal effect was 
observed after stimulation of the cells  with  KLP (473). The maximal effect of KAL 
and B1R reached 437 and 403 a.U respectively.   
In cells expressing rat B2R the minimal concentration for stimulation with des-Arg9-
BK, des-Arg10-KAL and des-Arg10-KLP was 1nm. The maximal response was 
reached at 10µM. The effective concentration (EC50) was 41.8nm for BK 63.7nM for 
KAL and 40.4nM for KLP. The maximal effect was approximately equal in all three 
agonists (ca 465 a.U). 
We can conclude that BK, KAL and KLP are similar potent agonist on the rat B2R. 
However, KLP displayed the strongest effect. Des-Arg-metabolites displayed 10,000-
fold smaller potency on the rat B2R. 
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4.3.4. Calcium signalling of cells expressing mouse B1R 
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Fig.4.54: Concentration-response relationship of des-Arg9-BK, des-Arg10-KAL and des-Arg10-KLP 
signalling on mouse B1R. 
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Fig.4.55: Concentration-response relationship of BK, KAL and KLP signalling on mouse B1R. 
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Agonist EC50 (M) Max effect 
des-Arg9-BK 1.5*10-9 414 
des-Arg10-KAL 3.5*10-9 398 
des-Arg10-KLP 1.3*10-9 403 
BK 2.0*10-6 284 
KAL 1.1*10-6 275 
KLP 1.3*10-6 328 
 
Tab.4.6: EC50 and maximal effect of kinin induced increase in [Ca2+]i in cells expressing mouse B1R. 
Data are means from at least three experiments.   
  
In cells expressing mouse B1R the lowest concentration des-Arg9-BK, des-Arg10-KAL 
and des-Arg10-KLP, that induced increase in [Ca2+]i was 0.01nM. The maximal 
response was achieved with 1000nM concentration of the des-Arg-metabolites. The 
effective concentration (EC50) was 1.5nM for des-Arg9-BK, 3.5nM for des-Arg10-KAL 
and 1.3nM for des-Arg10-KLP. The maximal effect was approximately equal in all 
three agonists and reached the value of 405 a.U. 
In cells expressing mouse B1R the minimal concentration for stimulation with BK, 
KAL and KLP was 10nm. The maximal response was reached at 100µM. The 
effective concentration (EC50) calculated from the concentration-response curves 
was 2µm for BK, 1.1µM for KAL and 1.3µM for KLP. KLP caused the highest 
maximal effect-328, whereas BK and KAL achieved the maximal effects of 280 a.U.  
We can conclude that in cells expressing mouse B1R the three des-Arg-metabolites 
were similar effective and potent. Again BK, KAL and KLP which are metabolites 
acting mainly on B2R were 1,000-fold less potent and also less efficacious agonists 
on the mouse B2R. 
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4.3.5. Calcium signalling of cells expressing mouse B2R 
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Fig.4.56: Concentration-response relationship of BK, KAL and KLP signalling on mouse B2R. 
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Fig.4.57: Concentration-response relationship of des-Arg9-BK, des-Arg10-KAL and des-Arg10-KLP 
signalling on mouse B2R. 
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Agonist EC50 (M) Max effect 
BK 4.1*10-12 570 
KAL 4.6*10-12 619 
KLP 3.1*10-12 742 
des-Arg9-BK 8.8*10-8 650 
des-Arg10-KAL 1.3*10-7 596 
des-Arg10-KLP 1.6*10-7 512 
 
Tab.4.7: EC50 and maximal effect of kinin induced increase in [Ca2+]i in cells expressing mouse B2R. 
Data are means from at least three experiments.   
 
In cells expressing mouse B2R the treshold concentration for stimulation with BK, 
KAL and KLP was 0.01pM and the maximal response was observed at 1nM. The 
effective concentration (EC50) calculated from the concentration-response curves 
was 4.1pM for BK, 4.6pM for KAL and 3.1pM for KLP. The strongest maximal effect 
was observed after stimulation of the cells with  KLP-742 a.U. The maximal effect of 
KAL and BK reached 619 and 570 a.U, respectively.   
In the cells expressing mouse B2R the minimal concentration of des-Arg9-BK, des-
Arg10-KAL and des-Arg10-KLP used for stimulation was 1nm and the maximal 
observed response was reached at a kinin concentration of 10µM. The effective 
concentration (EC50) calculated from the concentration-response curves was 
23.2µm for BK, 26.6µM for KAL and 23.6µM for KLP. The strongest maximal effect 
was 650 a.U mediated by des-Arg9-BK. The maximal effect of des-Arg10-KAL and 
des-Arg10-KLP reached 596 and 512 a.U, respectively. 
We can summarize that on mouse B2R KLP mediated the strongest effect. The 
potency of BK, KAL and KLP was approximately similar. On the mouse B2R des-Arg-
metabolites were 10,000-fold less potent than BK, KAL and KLP. The best efficacy 
from the des-Arg-metabolites demonstrated des-Arg9-BK, however on the mouse 
B2R des-Arg10-KLP and des-Arg10-KAL were more potent agonists. 
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4.3.6. Calcium signalling of cells expressing human B1R 
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Fig.4.58: Concentration-response relationship of des-Arg9-BK, des-Arg10-KAL and des-Arg10-KLP 
signalling on human B1R. 
 
Human B1R
-14 -12 -10 -8 -6 -4
0
100
200
300
400
500
600 BK
KAL
KLP
Agonist (log M)
F3
40
/F
38
0
 
Fig.4.59: Concentration-response relationship of BK, KAL and KLP signalling on human B1R. 
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Agonist EC50 (M) Max effect 
des-Arg9-BK 1.6*10-9 326 
des-Arg10-KAL 8.7*10-10 410 
des-Arg10-KLP 5.2*10-10 365 
BK 2.2*10-8 234 
KAL 2.8*10-8 279 
KLP 3.0*10-8 279 
 
Tab.4.8: EC50 and maximal effect of kinin induced increase in [Ca2+]i in cells expressing human B1R. 
Data are means from at least three experiments.   
 
In cells expressing human B1R the treshold concentration for stimulation with des-
Arg9-BK, des-Arg10-KAL and des-Arg10-KLP was 1pM and the maximal response was 
observed at 100nM. The effective concentration (EC 50) was 1.6nM for des-Arg9-BK, 
0.9nM for des-Arg10-KAL and 0.5nM for des-Arg10-KLP. The strongest effect was 410 
demonstrated by des-Arg10-KAL. Des-Arg10-KLP and des-Arg9-BK displayed a 
maximal effect of 365 and 326 a.U, respectively.  
In cells expressing human B1R the minimal concentration for stimulation with BK, 
KAL and KLP was 1nM. The maximal response was reached at 10µM. The effective 
concentration (EC50) was 23.2µm for BK, 26.6µM for KAL and 23.6µM for KLP. The 
maximal effect was equal after stimulation of the cells expressing human B1R with 
KAL and KLP (279 a.U). The weakest effect was demonstrated by BK with the value 
of 234 a.U.  
The data show that in the cells expressing human B1R the most potent and 
efficacious agonist was des-Arg10-KAL.  Des-Arg9-BK was approximately 5-fold less 
potent and also less efficacious than des-Arg10-KAL. The kinins, that are known to 
act mainly on B2R-BK, KAL, KLP were 10-100-fold less potent and also less 
efficacious than the three des-Arg-metabolites.  
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4.3.7. Calcium signalling of cells expressing human B2R 
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Fig.4.60: Concentration-response relationship of kinin (BK, KAL and -KLP) signalling on human B2R. 
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Fig.4.61: Concentration-response relationship of des-Arg9-BK, des-Arg10-KAL and des-Arg10-KLP 
signalling on human B2R. 
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Agonist EC50 (M) Max effect 
BK 9.3*10-12 677 
KAL 8.5*10-12 697 
KLP 8.5*10-12 586 
des-Arg9-BK 8.2*10-8 538 
des-Arg10-KAL 7.7*10-8 467 
des-Arg10-KLP 1.6*10-7 484 
 
Tab.4.9: EC50 and maximal effect of kinin induced increase in [Ca2+]i in cells expressing human B2R. 
Data are means from at least three experiments.   
 
In cells expressing human B2R the threshold concentration for stimulation with BK, 
KAL and KLP was 0.01pM and the maximal response was observed at a 
concentration of 1nM. The effective concentration (EC 50) calculated from the 
concentration-response curves was 9.3pM for BK, 8.5pM for KAL and 8.5pM for KLP. 
KAL depicts the strongest effect with a value of 697 a.U. The maximal effect of BK 
and KLP reached 677 and 586 a.U, respectively. 
The minimal concentration for stimulation with des-Arg9-BK, des-Arg10-KAL and des-
Arg10-KLP in cells expressing human B2R was 1nM. The maximal response was 
achieved with concentration in the value of 10µM. The effective concentration (EC50) 
was 81.6nm for des-Arg9-BK, 76.8nM for des-Arg10-KAL and 160nM for des-Arg10-
KLP. The strongest maximal effect was achieved with des-Arg9-BK (538 a.U). The 
maximal effect of des-Arg10-KAL and des-Arg10-KLP was approximately equal. 
To sum up, it can be said, that BK and KAL demonstrated the strongest potency and 
efficacy on the human B2R. The maximal effect achieved after stimulation with KLP 
was slightly lower than the effects of BK and KAL. Des-Arg-metabolites are 10,000 
times less potent and also less efficacious on the human B2R. Des-Arg9-BK caused 
the highest maximal effect and also the best potency from the des-Arg-metabolites. 
Des-Arg10-KLP displayed the weakest potency of all agonists (100,000-fold less 
potent than BK, KAL and KLP). 
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5. DISCUSSION 
 
In humans and animals many different studies provide very strong evidence of a 
causal link between salt intake and high blood pressure. The mechanisms by which 
dietary salt increases arterial blood pressure are not fully understood, but they seem 
related to the inability of the kidneys to excrete large amounts of salt. Independent of 
the rise in blood pressure, dietary salt also increases cardiac left ventricular mass, 
arterial thickness and stiffness, the incidence of strokes, and the severity of cardiac 
failure. Thus chronic exposure to a high-salt diet appears to be an important factor 
involved in the frequent occurrence of hypertension and cardiovascular diseases in 
human population. 
Blood pressure regulation and salt-water homeostasis is under control of the RAAS 
(Ferrario et al., 1990). In addition, they are influenced by the action of the KKS on 
two distinct systems. In the blood vessels, kinins directly lower blood pressure by 
releasing NO and indirectly by generating prostacyclins from the endothelial cells 
(Toda et al., 1989). The second main system is the kidney, where all components 
required to generate kinins have been localized (Vio et al., 1992). There are many 
reports dealing with the importance of kinins in regulating electrolyte and water 
excretion. Strong evidence favour the notion, that physiological action of the RAAS in 
blood pressure regulation and salt- water homeostasis is counterbalanced by the 
KKS.    
We designed an experiment that should help to clarify the role of KKS in regulating 
high salt and blood pressure mechanisms. Two rat strains were used for the study - 
the kininogen-deficient BNK rats and the wild type control BN rats. The rats of both 
strains were given standard diet (SD) and high salt (HS) diet in order to investigate 
the effect of high salt diet. Furthermore, the rats were treated with spironolactone 
(aldosterone antagonist) in order to analyse the effect of aldosterone blockade. 
Within the frame of this work we focused in BN and BNK rats on the regulation of 
NO, NO synthases (eNOS, iNOS, nNOS), adenosine receptors (A1AR, A2AAR, A2BAR 
and A3AR) and bradykinin receptors (B1R and B2R) under different experimental 
conditions (standard diet or high salt diet ± aldosterone blockade). 
Furthermore, we were interested in elucidating the effect of different kinins on the 
B1R and B2R. Until now the ligand-receptor interaction of kinins were mainly 
characterized in binding studies. We examined the concentration-response 
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relationship of kinin signalling by measuring intracellular calcium levels of HEK293 
cells stably expressing human, rat and mouse B1R and B2R. We believe, that the 
calcium signalling is a more reliable tool for squaring off effect of different kinins 
rather than binding studies. 
 
5.1. Kininogen-deficient BNK rats  
 
It is generally accepted that under normal conditions kininogen-deficient BNK rats 
show no apparent syndromes. However, after high salt diet BNK rats are known to 
develop hypertension. In BNK rats high salt diet (2% NaCl) evokes a rise in systemic 
blood pressure, increase in water admission, reduction in urine volume, and Na+-
level in the urine and a Na+-accumulation in erythrocytes (Majima et al., 1993). BNK 
rats show low levels of kininogen and prekallikrein in plasma (Hayashi et al., 1989).  
Furthermore, Kathori and Majima published, that BNK rats are incapable of excreting 
kinin in the urine. In contrast to these findings our group could detect kininogen as 
well as kinins in urine of BNK rats. Interestingly the activity of urinary KKS was shown 
to be slightly higher in BNK rats than in BN rats. The Na+-accumulation could be 
increased due to the effect of aldosterone. These finding led us to the question, 
whether the salt-induced hypertension in BNK rats could be induced by 
mineralocorticoide effect rather than by kininogen-deficiency (Lukasova, 2006).  
Therefore, our group investigated in BN and BNK rats the expression of enzymes 
that synthesize aldosterone and also the expression of mineralocorticoid receptors 
(MR). We could demonstrate that in both strains the expression of aldosterone 
synthases and also the aldosterone level were equal. However, in BNK rats we found 
a higher expression of MR. Furthermore, in BNK rats we could display a mutation in 
the sequence of MR. All these finding supported the hypothesis that the mutation and 
over-expression of MR could lead to an enhanced response of BNK rats to the 
mineralocorticoid action (Engel, 2006). Therefore when comparing the two strains we 
have to consider not only the kininogen-deficiency in BNK rats but also the possible 
diverse effect of mineralocorticoid action.  
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5.2. Nitric oxide production in urine and plasma of BN/BNK rats 
 
As a major vasodilatator NO plays crucial role in the blood pressure regulation. NO 
may be a principal mediator of pressure natriuresis. Therefore we have decided to 
investigate the level of NO metabolites-nitrates and nitrites (NOx) in urine and 
plasma of BN and BNK rats and so to elucidate if there is any difference in the NO 
production between these two strains. Next we wanted to elicit the role of high salt 
diet and aldosterone blockade on the NOx levels in both strains. 
We could determine that high salt diet significantly enhanced the urinary NOx level in 
both strains. The NOx levels remained elevated following high salt diet also after 
spironolactone treatment. This observation is consistent with increased urinary NOx 
excretion in Sprague Dawley rats (SD) placed on a high salt diet (Schultz and Tolins, 
1993; Tolins and Schultz, 1994). On the other hand, Bragulat and colleagues, 2001 
reported a decrease in NOx production after high salt intake in plasma as well as in 
urine of humans.  
We assume, that following high salt diet, the urinary NO production increases in 
order to increase the NaCl excretion. In hypertension is this mechanism probably 
altered and the hypertensive objects are not able to compensate high salt intake with 
enhanced NO production. This could explain, why hypertensive patients produce 
lower urinary NOx levels. 
It has been shown that mineralocorticoid receptor antagonists spironolactone and 
eplerenone appeared to increase bioavailable NO in humans (Furquaharson, 2000). 
Therefore we were interested in the effect of spironolactone on NO production in rats. 
According to our measurement spironolactone treatment in BN rats did not change 
significantly the urinary NOx level. In contrast to BN rats spironolactone treatment 
increased significantly the urinary nitrate levels in BNK rats. Under high salt diet no 
significant effect of spironolactone treatment on the NOx  production was observed. 
At variance with the findings of Furquaharson might be considered the investigation 
of Deng et al., 1996. He reported that urinary elimination of the metabolite of NO, 
nitrate, increases after Ang II stimulation, suggesting that NO synthesis increases in 
the renal vasculature. Because spironolactone acts also as a diuretic drug which 
enhanced the sodium excretion we would expect down-regulation of NO after 
spironolactone treatment rather than up-regulation. This idea is consistent with the 
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findings of Nava et al., 1996 who have reported that vasodilatators down-regulate the 
generation of NO. 
When comparing BNK and BN rats, we observed, that the NOx levels were slightly 
lower in BNK rats than in BN rats following standard and high salt diet as well as high 
salt diet and spironolactone treatment. As bradykinin is a direct stimulus for the 
production of NO it is not surprising to see that the kininogen-deficient BNK rats 
produced less NO. Surprisingly, in BNK rats treated with spironolactone the urinary 
NOx level were significantly higher than in BN rats. Yet we can not explain the 
enhanced production of NOx in BNK rats after spironolactone treatment. 
Next we were interested in the plasma NOx levels in BN and BNK rats. Nava et al., 
2000 have demonstrated that plasma nitrate assessments can be used as an indirect 
index to detect changes in NO production of endothelial origin.  
In both strains we could not determine any significant effect of high salt diet and of 
spironolactone administration on the plasma NOx production. High salt diet slightly 
decreased the plasma NOx production in both strains even after spironolactone 
treatment. This results are inconsistent with the data of Schultz and Tolins, 1993, 
who reported, that SD rats following high salt diet displayed increased levels of NOx 
in plasma. In contrast, other study on humans demonstrated decrease of NOx 
production after high salt intake in plasma as well as in urine (Bragulat et al., 2001).  
The changes of urinary NOx levels in the experimental groups did not correspond to 
the changes in plasma levels. It may be possible that NO production is increased in 
renal tubules at a time in which endothelial production is decreased.  We assume 
that increased dietary sodium might lead to enhanced NO production via up-
regulation of renal NOS isoforms or via up-regulation of bradykinin receptors.  
We could not confirm the finding of Furquaharson, 2000, who observed in humans 
higher bioavailability of NO after spironolactone treatment. We observed no 
significant change in the NOx plasma level and so no signal, that the NO production 
in the cardiovascular system would be increased after the blockade of 
mineralocorticoid receptor. 
When comparing both strains, in all experimental groups the plasma NOx levels in 
BNK rats were lower than in BN rats. Significantly lower NOx levels in BNK rats were 
found in the experimental group fed with high salt diet and in after spironolactone 
treatment. This finding corresponds as well to the fact, that BNK rats have lower 
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amount of kinins in plasma. As kinins stimulate the NO production, it is obvious that 
the plasma NOx levels in BNK rats will be lower than in BN rats. 
 
5.3. Nitric oxide synthases expression in the kidney of BN/BNK rats 
 
Besides NO metabolites we also investigated the expression of all three NOS 
isoforms in the kidney of both strains. The regulation of NO synthesis in the kidney by 
NOSs is complex and incompletely understood. All three major isoforms of NOS 
(eNOS, INOS and nNOS) are constitutively expressed in kidney (Kone and Baylis, 
1997). In general, renal NOS is considered to be responsible for production of NO, 
which plays an important role in the regulation of renal hemodynamics including 
tubuloglomerular feedback and renin release (Kone, 1997). In addition NO is thought 
to influence tubular sodium reabsorption through changes in renal medullary blood 
flow and sodium reabsorption (Mattson et al., 1992).  
It is generally accepted that eNOS, found in the vascular endothelium, is important in 
blood flow control. The localization of nNOS and iNOS in the vasculature and/or 
macula densa indicates, that these isoforms may also play a role in blood flow 
regulation during physiological or patophysiological conditions. Moreover, NO 
synthesis from macula densa is stimulated by the vasocontrictors angiotensin II, 
noradrenaline and vasopressin (Cowley et al., 2003). Nevertheless, the functional 
importance of the different NOS isoforms in the regulation of renal blood flow is still 
not clear.  
We could determine that aldosterone influences the nNOS expression in the kidney 
of both, BN and BNK rats. Spironolactone (aldosterone antagonist) significantly 
decreased the nNOS expression. Moreover, spironolactone lowered the nNOS 
expression in both strains also under high salt diet. The data suggest, that 
aldosterone causes a similar response in nNOS regulation as angiotensin II, which 
increases the NO synthesis in macula densa cells as reported by Deng et al., 1996. 
In contrast to nNOS, in the kidney of both strains spironolactone treatment slightly 
increased the expression of iNOS and eNOS. However, the difference was not 
significant. Recent studies showed that spironolactone increased expression of 
eNOS in the kidney of rats and increased bioavailability of NO in humans 
(Furquharson, 2000).  
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Our data indicate, that aldosterone differently regulates the expression of NOS 
isoforms. On one hand aldosterone increases the nNOS expression and on the other 
hand lowers the expression of iNOS and eNOS.  
 
Furthermore, we examined the effect of high salt diet on the expression of NOS 
isoforms. In BN rats following high salt diet we could observe a moderate elevation in 
the expression of all three NOS isoforms. In BNK rats an opposite trend in the gene 
expression was observed. High salt diet lowered the nNOS and iNOS-mRNA 
expression.  However, following high salt these changes of gene expression were not 
statistically significant. The findings of other authors are inconsistent. Some authors 
have shown that increased dietary sodium increase the expression of NOS isoforms 
in SD rats (Schutz and Tolins, 1993; Mattson and Higgins, 1996). On the other hand, 
Ni and Vazari, 2001 reported a down-regulation of all three NOS isoforms in the 
same rat strain.  
The data suggest, that the NOS expression differs between the control BN and 
kininogen-deficient BNK rats. Under standard diet the expression levels of all three 
isoforms were similar. However, after salt loading BNK rats displayed lower 
expression of nNOS and iNOS. In BN rats the increased expression of NOS following 
high salt diet could explain the elevated NOx levels in urine. Moreover, the 
decreased nNOS and iNOS expression together with lower NOx levels could be one 
of the explanations for the higher sensitivity of BNK rats vs. BN rats towards high salt 
diet. 
In conclusion we can say that the regulation of NO and NOS in the kidney is a 
complex system. Increased salt intake elevated the levels of NOx in the urine but not 
in the plasma of the rat. Moreover, aldosterone influenced differentially the 
expression of NOS isoforms-increased nNOS expression and decreased iNOS and 
eNOS expression. Additionally, kininogen-deficiency led to the decreased NO 
production and to the lower NOS expression in the kidney. 
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5.4. Adenosine receptors expression in the kidney of BN/BNK rats 
 
Adenosine is a vasoactive metabolite of ATP hydrolysis that is involved in the 
regulation of renal haemodynamics, tubular reabsorption and renin release. Elevated 
tissue levels are found under ischemia and renal injury (Castrop, 2007). Adenosine 
levels increase following high dietary sodium intake (Zou et al., 1999).  
All classes of adenosine receptors are expressed in the kidney including the receptor 
responsible for vasocontriction, A1AR, for vasodilatation A2AAR and A2BAR, and 
A3AR, with a role as a possible modulator of the renal vascular resistance. 
The gene expression studies of ARs showed different regulation of the receptor 
expression. We found no mediators of regulation of the expression of A2AAR and 
A2AAR in the kidney of both strains. Neither high salt nor spironolactone affected their 
expression. In contrast, aldosterone seem to be involved in the regulation of A1AR 
and A3AR-mRNA expression. Spironolactone (aldosterone antagonist) significantly 
down-regulated both receptors, A1AR and A3AR, in the kidney of BN as well as BNK 
rats. Spironolactone elicited the same effect also after high salt diet. The results 
suggest that in the kidney aldosterone increases the expression of A1AR and A3AR. 
This indicates that the down-regulation of vasoconstrictor A1AR after spironolactone 
treatment could be one of the protective actions of spironolactone. We can not 
predicts the consequences of decreased A3AR expression in the kidney because the 
exact function of A3AR is not clear.   
High salt diet decreased the A1AR expression and increased the A3AR in both, BN 
and BNK rats. These results are consistent with the finding of Zou et al., 1999. We 
assume that the decrease of A1AR expression is a possible mechanism that reduces 
the vasoconstriction and so enhances the excretion of sodium.  
As we could not determine any differences in the expression of A1AR, A2AAR, A2AAR 
and A3AR between the BN and BNK rats. We can conclude that the kininogen 
deficiency does not affect the expression of these receptors in the kidney. 
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5.5. Bradykinin receptors expression in the kidney of BN/BNK rats 
 
The renal KKS seems to participate in both intrarenal and extrarenal complex events 
such as control of the extracellular volume, regulation of blood pressure, and control 
of sodium and water excretion, renal vascular resistance, and rennin release. Both 
bradykinin receptors, B1R and B2R were reported to be present in the kidney. B2R is 
localized mainly on the epithel cells of medullary collecting duct, in glomerulus and in 
the tubular system of the nephron (Katori and Majima, 2003). Under physiological 
conditions B1R is very low expressed in the rat kidney, but the expression can be 
induced following various stimuli (Castano et al., 1998).  
The use of selective B1R and B2R antagonists in volume-loaded rats suggests, that 
the natriuretic and vasodilatator effect of endogenous kinins is mediated by B2R, 
whereas B1R blockade reduces the glomerular filtration rate (Fenoy and Roman, 
1992). Duka et al., 2001 reported, that when B1R become upregulated, it can assume 
a part of hemodynamics properties of B2R. Furthermore, they assumed that in tissue 
that are particularly vulnerable to hypertensive damage experimental manipulations 
to produce hypertension seem to induce significant upregulation of the B1R, but not 
of the B2R. 
Little is known about the regulation of B2R and B1R in the kidney following increased 
salt loading. There is only one publication of El-Dahr, 1996 which showed, that in 
newborn rats high salt consumtion increased the B2R in the developing kidney.  
The expression analysis in the kidney showed, that the B2R expression following high 
salt diet spironolactone administration remained unchanged in both strains. There 
were no differences found in the expression of B2R between BN and BNK rats. This 
finding is in agreement with the results of Bacharov et al., 2001, who reported that 
B2R in the kidney is constitutively expressed and highly conserved. 
We showed for the first time, that high salt diet increases the B1R expression in the 
kidney of rats. The B1R expression following high salt diet increased in both strains, 
BN and BNK rats. However, the increase was significant only in BN rats, but not in 
BNK rats. BNK rats following high salt diet displayed lower levels of B1R expression, 
nevertheless the difference was not statistically significant. In addition, we found that 
spironolactone administration did not influence the expression of B1R. 
In conclusion, increased salt intake regulates the B1R but not the B2R expression in 
both strains. Increased B1R expression might be one of the protective mechanisms of 
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the kidney against high salt intake. Kininogen deficiency of BNK rats after high salt 
diet resulted in lower B1R expression in comparison to control BN rats. The lower 
B1R expression in the kidney of BNK rats could contribute to the higher sensitivity of 
BNK rats vs. BN rats towards high salt diet. In addition, aldosterone seems to have 
no effect on the bradykinin receptors expression. 
 
5.6. Gene expression in the atria of BN/BNK rats 
 
The expression analysis of the atria showed no change in the expression of NOS 
isoforms, adenosine receptors and bradykinin receptors following high salt diet 
and/or spironolactone administration. This results indicate, that neither high salt 
intake nor aldosterone regulate the expression of NOS isoforms, adenosine 
receptors and bradykinin receptors. Moreover, the results showed that kininogen 
deficiency has no effect on the regulation of the analysed genes.  
 
5.7. Nitric oxide synthases expression in the ventricles of BN/BNK rats 
 
In cardiovascular system, NO generation from endothelium is important to maintain 
the vasculature in a relaxed state, inhibit the adhesion of platelets and white cells and 
supress the replication of smooth-muscle cells (Napoli and Ignarro, 2001). Inhibition 
of NOS causes vasoconstriction and hypertension in animal models (Cayatte et al., 
1994). Moreover, previous studies have suggested that salt-sensitive hypertension in 
humans and experimental animals may in part be due to dysregulation of the nitric 
oxide system. 
This study was conducted to determine effect of salt load and spironolactone 
administration on the nNOS, eNOS and iNOS expressions in the ventricles of control 
BN rats and kininogen deficient BNK rats. 
Following high salt diet and after spironolactone administration we found a significant 
down-regulation of nNOS-mRNA expression in the ventricles of BNK rats, but not in 
BN rats. In BNK rats high salt diet in combination with spironolactone significantly  
up-regulated the nNOS expression in comparison to high salt diet alone. 
Recent study reported, that NO derived from nNOS has a positive ionotropic effect, 
possibly secondary to activation of sarcoplasmic-reticulum calcium release (De 
Santis et al., 1999). Interestingly, the changes of the heart rate (reported by 
Lukasova, 2006) corresponded to the nNOS expression in ventricles of BN and BNK 
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rats. We can conclude that following high salt diet and after spironolactone 
administration BNK rats demonstrated lower nNOS expression and also lower heart 
rate than BN rats. Under standard diet and high salt diet in combination with 
spironolactone opposite effect was determined-higher nNOS expression and higher 
heart rate in BNK rats than in BN rats. 
To summarize, our findings indicate that in BNK rats high salt diet lowered the nNOS 
expression and also the  heart rate. In contrast, in BNK rats  aldosterone increased 
nNOS expression as well as heart rate.   
Next we were interested in the expression of iNOS in the heart. Expression of iNOS 
has been implicated as a key mediator of ischemic preconditioning in the heart 
(Nandagopal et al., 2002). Our experiments showed, that under standard salt diet the 
iNOS-mRNA expression was 21-fold lower in BNK rats than in BN rats. In BN rats 
high salt diet and/or spironolactone displayed no significant effect on iNOS-mRNA 
expression. However, in BNK rats following high salt diet and spirolactone 
administration the iNOS-mRNA expression significantly increased.  
In conclusion, the study revealed a marked upregulation of iNOS synthase following 
high salt diet in BNK, but not in BN rats. Furthermore, we demonstrated that 
aldosterone decreases the iNOS expression in ventricles of BNK, but not BN rats.  
The studies on eNOS revealed that eNOS is a very important regulator of endothelial 
NO production. In addition, eNOS knockout mice are hypertensive and more prone to 
atherogenesis (Kuhlencordt et al., 2001). In the heart eNOS seem to have different 
and sometimes opposing effects than nNOS  (Barouch et al., 2002). The activity of 
eNOS decreases ß-adrenoreceptor-induced contractility, whereas nNOS has a 
positive ionotropic effect (De Santic et al., 1999).  
We were interested which role plays salt and aldosterone in the eNOS regulation in 
ventricles of BN and BNK rats. We have shown that under standard diet the level of 
eNOS expression in ventricles of BNK rats is significantly lower than the eNOS 
expression in BN rats. Such a difference we could observe under standard diet also 
in the expression of iNOS as described above. In BN rats following high salt diet 
and/or spironolactone remained the eNOS expression unchanged. In BNK rats after 
increased salt intake and aldosterone blockade we could determine upregulation of 
the eNOS expression. Nevertheless, the difference was statistically significant only 
after the combination of both, high salt diet and spironolactone. 
DISCUSSION 
111 
In conclusion, our data suggest that high salt diet and aldosterone influence the 
regulation of NOS isoforms in BNK rats, but not in BN rats. In BN rats we found no 
significant difference in the expression of all three NOS isoforms between the 
experimental groups. In BNK rats following high salt diet we found decreased nNOS 
and increased eNOS and iNOS expression. Furthermore, spironolactone in BNK rats 
decreased nNOS and increased eNOS expression. Under standard diet BNK rats 
displayed significantly lower expression of eNOS and iNOS in the ventricles than BN 
rats.  However, after high salt intake and/or spironolactone treatment the expression 
of both, eNOS and iNOS increased and reached similar levels as BN rats. The 
increased expression of eNOS and iNOS after high salt intake in BNK rats might be a 
protective mechanism against high blood pressure.  
 
5.8. Adenosine receptor expression in the ventricles of BN/BNK rats 
 
Adenosine appears to directly protect cardiomyocytes or myocardial tissue agains 
ischemia. Moreover, adenosine was reported to have antiadrenergic effect. 
Endogenouse adenosine may protect via one or all of the four characterized AR 
subtypes-A1-, A2A-, A2B- and A3ARs. All adenosine subtypes are expressed in 
cardiovascular cells (Pearth et al., 2000; Zhao et al., 1993, Black et al., 2002). The 
overexpression of A1AR was reported to significantly reduce heart rate and to 
improve the contractility of cardiomyocytes (Haedrick, 1999). 
The regulation of the ARs in the heart was not investigated until now. We examined 
the role of high salt diet and/or spironolactone in the regulation of the expression of 
all adenosine receptor subtypes. We found no significant effect of high salt diet 
and/or spironolactone on the expression of A1-, A2A-, A2B-AR in the heart of BN and 
BNK rats. Therefore we assume, that neither high salt nor aldosterone affect the A1-, 
A2A-, A2B-AR expression in heart. 
Nevertheless, we determined that high salt diet alone and in combination with 
spironolactone significantly down-regulated the A3AR in BNK rats, but not in BN rats. 
In BN rats increased salt intake enhanced the A3AR expression. Because adenosine 
is though to have a protective effect in the heart also via A3AR, decreased expression 
of A3AR in BNK rats could contribute to worse heart protection  after salt loading. The 
increase of A3AR expression in BN rats might be one of the protective mechanisms 
against increased salt intake.  
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Furthermore, we found that spironolactone significantly decreases the A3AR 
expression in BNK rats. In BN rats spironolactone also downregulated the A3AR 
expression, but the difference was less evident. The different regulation of A3AR 
expression in BNK rats we could explain as an enhanced response of BNK rats to 
the mineralocorticoid action that was determined earlier in other experiments of our 
research group (Lukasova, 2006; Engel, 2006). It was reported, that aldosterone 
promotes in the cardiovascular system cardiac hypertrophy and abnormal vascular 
endothelial function (Delcayre, 2000). We suppose that increase of A3AR expression 
might be one of the protective mechanisms of the heart against the action of 
aldosterone.  
When comparing the ARs expression between BN and BNK rats,  we can say, that 
the expression of ARs did not significantly differ between the two rat strains. 
Nevertheless, the expression of A1AR was slightly lower in BNK rats of all 
experimental groups than in BN rats. We assume, that kininogen deficiency might  
evoke the lower expression of cardioprotective A1AR and so to contribute to the 
worse heart protection in BNK rats in comparison to BN rats. This finding is 
supported with a lower A3AR expression in heart of BNK rats following high salt diet.  
 
5.9. Bradykinine receptor expression in the ventricles of BN/BNK rats 
 
All the components of the kallikrein-kinin system are located in the vascular smooth 
muscle as well as in the heart. In recent years, numerous observations obtained from 
clinical and experimental models of diabetes, hypertension, cardiac failure, 
ischaemia, myocardial infarction and left ventricular hypertrophy, have suggested 
that the reduced activity of the local kallikrein-kinin system may be instrumental in the 
induction of cardiovascular-related diseases. The ability of kallikrein gene delivery to 
produce a wide spectrum of beneficial effects makes it an excellent candidate in 
treating hypertension, and cardiovascular and renal diseases (Scharma, 2002). 
Kinins counterbalance the pressor effect of angiotensin II, salt and mineralocorticoids 
(Linz and Scholkens, 1992). The vasodilatative effect of kinins is under normal 
conditions mediated by the B2R (Weldon et al., 1995), but it is known that under 
inflammatory conditions, newly expressed B1R can also mediate kinin-induced 
vasodilatation and hypotension (Regoli et al., 1981). Furthermore, B2R have been 
primarily implicated in the preconditioning and cardioprotective effects of BK (Baxter 
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and Ebrahim, 2002), but it was determined that cardiac ischemia can induce B1R 
locally providing a basis that B1R activity may also promote preconditioning and 
cardioprotection (Bouchard et al., 1998).    
The investigation of Alfie et al., 1996 showed, that B2R gene knockout mice had 
accelerated development and accentuated severity of salt-induced hypertension, as 
well as more pronounced cardiac hypertrophy than their wild-type controls. However, 
there is no study, that would investigate the influence of high salt diet or aldosterone 
on the B1R and B2R expression in the heart. 
Our data suggest that aldosterone has no influence on the B2R expression in both, 
BN and BNK rats. Next, we could demonstrate that high salt lowered significantly the 
B2R expression in BNK rats, but not BN rats. We could show that the B2R expression 
did not significantly differ between BN and BNK rats. Nevertheless, BNK rats 
following high salt diet displayed lower levels of B2R-mRNA.  
We examined further the B1R expression in heart of BN and BNK rats in all 
experimental groups. We found that in BN rats after salt loading the B1R expression 
increased. In contrast, in BNK rats high salt diet lowered the B1R expression. In 
addition, aldosterone seem to have no significant effect on B1R expression in heart of 
both, BN and BNK rats. Nevertheless, spironolactone administration slightly lowered 
the B1R expression in both strains.  
In addition, we found lower B1R expression in BNK rats, in all experimental groups, 
than in BN rats. This suggest that kininogen deficiency downregulates the B1R 
expression in heart. Lower B1R and B2R-mRNA expression after high salt intake  in 
the heart of BNK rats could lead to decreased action of kinins and so to contribute to 
the development of  hypertension. 
 
5.8. Determination of kinin efficacy and potency on B1R  and B2R of human, rat 
and mouse 
 
In all mammalian species the B2R has a high affinity for "native" kinins, BK and KAL. 
Kallidin was reported to have a significant affinity on the human and rabbit B1R, but 
not on the mouse B1R (Leeb-Lundenberg et al, 2005). Furthermore, it was assumed 
that BK is the only kinin in rodent as no KAL has been detected so far. Recently our 
group found a kallidin-like-peptide (KLP), a novel kinin agonist in the rat (Hilgenfeldt 
et al., 2005). 
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The most discriminative structural determinant for high affinity at all mammalian B1R 
is the removal of the C-terminal arginine, which at the same time is detrimental for 
affinity toward the B2R. The binding studies demonstrated that des-Arg10-KAL has a 
higher affinity for human and rabbit B1R than des-Arg9-BK (Hess, 1994), however, 
the pharmacological profile varies in the rodents (rat and mouse). Hess et al., 1996 
reported that des-Arg9-BK has a higher potency to B1R in rodent than des-Arg10-KAL. 
On the basis of the data mentioned above, we decided to prove the efficacy and 
potency of kinins, including the novel agonist KLP and its des-Arg-metabolite on cell 
lines expressing B1R/B2R of different species. Until now the ligand-receptor 
interaction of kinins were mainly characterized in binding studies. We decided to 
elucidate the effects of kinins by determination of intracellular calcium mobilization. 
Determination of intracellular calcium mobilization is the one of the most often used 
approach to measure activation of some GPCRs, especially those coupled to G-
proteins from the Gq/11 subfamily.  
We systematically compared the effects of BK, KAL, KLP, des-Arg9-BK, des-Arg10-
KAL and des-Arg10-KLP on the intracellular calcium concentration of Flp-In TREx-
HEK293-cells stably expressing human, rat and mouse B1R/B2R using calcium-
sensitive dye FURA-2. The measurement of intracellular calcium concentration 
provided a high sensitivity tool of receptor activation. Stimulation of B2R with kinins 
produced a calcium spike typical for Gq/11 coupled receptors: fast and of a high 
magnitude. B1R stimulation elicited also a fast signal of a high magnitude but the 
signal was more sustained, characterized by a plateau of elevated Ca2+.   
To find out, if the non-transfected cells express B1R and B2R, we measured the 
effects of kinins in HEK293. Des-Arg-metabolites did not evoke any calcium 
transients in HEK293 cells suggesting, that there is no B1R present. Stimulation with 
BK, KAL and KLP elicited a moderate calcium increase, however the efficacy and 
potency was very low. We can conclude that HEK293 cells are a suitable cell line 
providing no background signal after stimulation with des-Arg-metabolites of kinins 
and a very low signal following stimulation with BK, KAL and KLP. 
We found that in all three species (rat, mouse and human) BK, KAL and KLP elicited 
similar potencies and efficacies on the B2R. KAL demonstrated the highest efficacy 
on B2R of human. The novel agonist KLP, which was documented in rat, induced the 
highest efficacy on the B2R of rat and mouse. The des-Arg-metabolites were 10,000-
fold less potent on the B2R of rat, mouse and human. The efficacy of des-Arg-
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metabolites was equal or slightly lower than the efficacy of "native" kinins acting on 
B2R.  
In cells expressing B1R the effects des-Arg-metabolites displayed similar potencies 
and efficacies in all three species. In cells expressing human B1R des-Arg10-KAL 
mediated the strongest effect and demonstrated also the best potency.  Des-Arg10-
KLP displayed the best potency on B1R of rat. The potencies of des-Arg9-BK and 
des-Arg10-KLP were equal on mouse B1R. The kinins acting mainly on B2R, BK, KAL 
and KLP, were less efficacious in all three species. BK, KAL and KLP demonstrated 
100-fold lower potencies on B1R of human and rat and 1000-fold lower potencies on 
mouse B1R.   
In conclusion, the efficacies and potencies of BK, KAL and KLP were similar on B2R 
rat, mouse and human. The effects of des-Arg-metabolites evoked on B1R of all three 
species were also similar. We could show, that the novel agonist KLP is similarly 
efficacious and potent as BK and KAL on the rat, mouse and human B2R. 
Furthermore, we could prove, that the novel agonist des-Arg10-KLP is similarly 
efficacious and potent as des-Arg9-BK and des-Arg10-KAL on the rat, mouse and 
human B1R. 
We believe that the determination of intracellular calcium mobilization is a better tool 
for establishment of the kinins activity than the binding studies, which were used until 
now for the pharmacological characterization of the kinins. We also assume that the 
affinity of kinins on the B1R and B2R does not correspond with the efficacy and 
potency of the kinins. 
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6. SUMMARY  
 
Large amount of experimental and clinical studies has emphasized the crucial role of 
sodium in the regulation of blood pressure and the implications of an abnormal 
sodium balance in the development of hypertension in animal models as well as in 
humans. Salt sensitivity is definitely a multifactorial phenomenon involving extrinsic, 
essentially hormonal, as well as intrinsic renal tubular and haemodynamic 
mechanisms modulated by genetics factors.  
Several hormonal and autocrine systems have been involved in the pathophysiology 
of hypertension and of salt  sensitivity including the RAAS, KKS, NO and adenosine 
system. We examined the regulation of NO, NOS, adenosine receptors and 
bradykinin receptors in BNK rats and control BN rats. BNK rats are characterized by 
plasma kininogen deficiency that is reflected in lower levels of plasma kallikrein 
activity and consequently in lower plasma kinin levels. Moreover, BNK rats are 
known to develop rapid hypertension after increased salt intake.  
The functional interactions and regulation of NO, NOS, adenosine receptors and 
bradykinin receptors were examined under standard and high salt diet. Furthermore, 
the effect of aldosterone blockade was examined using spironolactone.  
Kininogen deficiency of BNK rats resulted in lower levels of NO metabolites in 
plasma and in urine of almost all experimental groups. NO is an important 
vasodilatator and increases sodium excretion in the kidney. The decreased NO 
production in BNK rats is probably one of the reason for development of salt sensitive 
hypertension. This finding was supported also by the expression studies. BNK rats 
fed with high salt diet displayed lower expression of iNOS and nNOS. 
Furthermore, kininogen deficient BNK rats displayed lower levels of B1R expression 
in the kidney. B1R was reported to assume a part of hemodynamics properties of 
B2R. Therefore, decreased B1R expression in the kidney of BNK rats could also 
contribute to impaired sodium excretion.  
Moreover, in BNK rats high salt diet decreased the expression of A3AR in kidney as 
well as in ventricles. A3AR is supposed to have a protective role against ischemia. 
The lower expression level of protective A3AR could also contribute to the 
development of hypertension in kininogen-deficient BNK rats.  
Increased salt intake resulted in decreased B1R and B2R expression in ventricles of 
BNK rats vs. BN rats. Both bradykinin receptors mediate protective effects in the 
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heart. In the ventricles of BNK rats compared to BN control rats lower B1R and B2R 
may be responsible for the development of hypertension and impaired 
cardioprotective effects of kinins. 
We could show that high salt diet increased urinary NOx levels in both strains. This is 
supposed to be a protective mechanism of the kidney as it enhances the excretion of 
sodium. In the kidney of both strains following high salt diet increased the expression 
of B1R and A3AR. However, the upregulation was only significant in BN rats. Both 
receptors were reported to have protective renal effects, therefore we assume, that 
the upregulation of these receptors could be a regulatory mechanism that helps to 
increase the sodium excretion.  
Moreover, we found that aldosterone is involved in the regulation of A1AR, A3AR and 
nNOS in the kidney of both strains. In contrast, in ventricles of BNK but not of BN rats 
aldosterone seems to be involved in the regulation of A3AR, nNOS and iNOS 
expression. 
 
In addition, we elucidated the concentration-response relationship of kinin signalling 
by measuring intracellular calcium levels of HEK293 cells expressing human, rat and 
mouse B1R and B2R.  We showed that KLP-the novel agonist found by our group is 
similarly efficacious and potent as BK and KAL on the rat, mouse and human B2R. 
Moreover, we demonstrated that des-Arg10-KLP, the metabolite of the novel agonist 
KLP is similarly efficacious and potent as des-Arg9-BK and des-Arg10-KAL on the 
B1R. We conclude, that the action of BK, KAL and KLP is similar on B2R and the 
action of des-Arg9-BK, des-Arg10-KAL and des-Arg10-KLP is similar on the B1R.  
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